RXFP1 agonist

Abstract

The present disclosure relates to compounds of formula (I), which are RXFP1 receptor agonists, to compositions containing them, and to methods of using them in the treatment of, for example, heart failure, fibrotic diseases, and related diseases such as pulmonary disease (e.g., idiopathic pulmonary fibrosis), renal disease (e.g., chronic kidney disease), or liver disease (e.g., nonalcoholic steatohepatitis and portal hypertension). TIFF2024540161000049.tif33130

Description

[Technical field]

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 273,290, filed October 29, 2021, the disclosure of which is incorporated herein by reference in its entirety.

[0002] The present disclosure relates to novel compounds that are relaxin family peptide receptor 1 (RXFP1) agonists, compositions containing them, and methods of using them in the treatment of, for example, heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), and liver disease (e.g., non-alcoholic steatohepatitis and portal hypertension). [Background technology]

[0003] Human relaxin hormone (also called relaxin or H2 relaxin) is a 6 kDa peptide composed of 53 amino acids whose activity was first discovered in 1926 when Frederick Hisaw observed relaxation of the fibrocartilaginous symphysis pubis joint when a crude extract from porcine corpora lutea was injected into virgin guinea pigs (Hisaw FL, Proc. Soc. Exp. Biol.Med., 1926, 23, 661-663). The relaxin receptor, formerly known as Lgr7, is now formally called relaxin family peptide receptor 1 (RXFP1) and was de-orphanized as a relaxin receptor in 2002 (Hsu SY. et al., Science, 2002, 295, 671-674). RXFP1 is reasonably well conserved between mouse and human with 85% amino acid identity and is essentially ubiquitously expressed in humans and other species (Halls ML. et al., Br. J.Pharmacol., 2007, 150, 677-691). The relaxin and RXFP1 cell signaling pathways are cell type dependent and highly complex (Halls ML. et al., Br. J.Pharmacol., 2007, 150, 677-691;Halls ML. et al., Ann. NY Acad. Sci., 2009, 1160, 108-111;Halls ML. et al., Ann. NY Acad. Sci., 2007, 1160, 117-120). The most studied pathway is one in which relaxin functions as an RXFP1 agonist, promoting GαS coupling and activation of adenylate cyclase, resulting in a relaxin-dependent increase in cellular levels of cAMP (Halls ML. et al., Mol. Pharmacol., 2006, 70, 214-226).

[0004] Since the initial discovery of relaxin, many experimental studies have focused on clarifying the role relaxin plays in female reproductive biology and on elucidating the physiological changes that occur during mammalian pregnancy (Sherwood OD., Endocr. Rev., 2004, 25, 205-234). During human pregnancy, to meet the nutritional demands imposed by the fetus, the female body undergoes a significant decrease in systemic vascular resistance (SVR) of approximately 30% with a concomitant increase in cardiac output of approximately 50% (Jeyabalan AC., KP, Reanl and Electrolyte Disorders. 2010, 462-518), (Clapp JF & Capeless E., Am. J. Cardio., 1997, 80, 1469-1473). Further vascular adaptations include an approximately 30% increase in systemic arterial compliance, which is important for maintaining effective ventricular-arterial coupling, as well as an approximately 50% increase in both renal blood flow (RBF) and glomerular filtration rate (GFR), which are important for the clearance of metabolic waste products (Jeyabalan AC., KP, Reanl and Electrolyte Disorders. 2010, 462-518), (Poppas A. et al., Circ., 1997, 95, 2407-2415). Both preclinical studies in rodents as well as clinical studies conducted in various patient settings provide evidence that relaxin is involved, at least to some extent, in mediating these adaptive biological changes (Conrad KP., Regul Integr. Comp. Physiol., 2011, 301, R267-275), (Teichman SL. et al., Heart Fail. Rev., 2009, 14, 321-329).Importantly, many of these adaptive responses may benefit HF patients in that excessive fibrosis, low arterial compliance, and reduced renal function are all common characteristics in patients with heart failure (Mohammed SF. et al., Circ., 2015, 131, 550-559), (Wohlfahrt P. et al., Eur. J. Heart Fail., 2015, 17, 27-34), (Damman K. et al., Prog. Cardiovasc. Dis., 2011, 54, 144-153).

[0005] Heart failure (HF), defined as a hemodynamic condition in which the cardiac pump function is impaired and as a result of insufficient systemic perfusion to meet the metabolic needs of the body, is prevalent in an estimated 5.8 million people in the United States and more than 23 million people worldwide, and represents an enormous burden in today's health care systems (Roger VL. et al., Circ. Res., 2013, 113, 646-659). It is estimated that by 2030, an additional 3 million people will have HF in the United States alone, a 25% increase from 2010. The estimated direct costs associated with HF in 2010 (in 2008 dollars) were $25 billion, projected to rise to $78 billion in 2030 (Heidenreich PA. et al., Circ., 2011, 123, 933-944). Surprisingly, one in nine deaths in the United States is indicated as having HF on the death certificate (Roger VL. et al., Circ., 2012, 125, e2-220), and although survival rates after a diagnosis of HF have improved over time (Matsushita K. et al., Diabetes, 2010, 59, 2020-2026) (Roger VL. et al., JAMA, 2004, 292, 344-350), mortality remains high, with approximately 50% of HF patients dying within 5 years of diagnosis (Roger VL. et al., Circ., 2012, 125, e2-220) (Roger VL. et al., JAMA, 2004, 292, 344-350).

[0006] Symptoms of HF are the result of insufficient cardiac output and can be quite debilitating depending on the stage of disease progression. The main signs and symptoms of HF include: 1) dyspnea (labored breathing) resulting from pulmonary edema caused by ineffective forward flow from the left ventricle and increased pressure in the pulmonary capillary bed; 2) leg edema, which occurs when the right ventricle cannot match the systemic venous return; and 3) fatigue due to the inability of heart failure to maintain sufficient cardiac output (CO) to meet the metabolic demands of the body (Kemp CD. & Conte JV., Cardiovasc. Pathol., 2011, 21, 365-371). Also, in relation to the severity of symptoms, HF patients are often described as "compensated" or "decompensated". In compensated heart failure, symptoms are stable and many obvious features such as fluid retention and pulmonary edema are absent. Decompensated heart failure refers to an exacerbation that may be manifested as acute episodes of pulmonary edema, reduced exercise tolerance, and increased shortness of breath on exercise (Millane T. et al., BMJ, 2000, 320, 559-562).

[0007] Contrary to the simple definition that the cardiac function may be impaired leading to an inability to meet metabolic demands, the numerous causative diseases, the numerous risk factors, and the many pathological changes that ultimately lead to heart failure make this disease extremely complex (Jessup M. & Brozena S., N. Engli. J. Med., 2003, 348, 3007-2018). The adverse events thought to be involved in the pathophysiology of HF range from very acute events such as myocardial infarction to chronic damage such as lifelong hypertension. Historically, HF has been primarily described as "systolic HF", where reduced left ventricular (LV) contractile function limits blood ejection, resulting in a reduced ejection fraction (EF = stroke volume / end-diastolic volume), or as "diastolic HF", where active relaxation reduces LV filling during diastole and passive stiffness increases it, but overall EF is preserved (Borlaug BA. & Paulus WJ., Eur Heart J., 2011, 32, 670-679). More recently, new terms have been adopted: "heart failure with reduced ejection fraction" (HFrEF) and "heart failure with preserved ejection fraction" (HFpEF), as it has become understood that diastolic and systolic LV dysfunction are not unique and specific to these two groups (Borlaug BA. & Paulus WJ., Eur Heart J., 2011, 32, 670-679). Although these two patient populations show very similar signs and symptoms, it is currently under debate within the cardiovascular community whether HFrEF and HFpEF represent two distinct forms of HF or two extremes of a single spectrum sharing a common pathology (Borlaug BA. & Redfield MM., Circ., 2011, 123, 2006-2013), (De Keulenaer GW. & Brutsaert DL., Circ., 2011, 123, 1996-2004).

[0008] Serelaxin, an intravenous (IV) formulation of human recombinant relaxin peptide with a relatively short phase 1 pharmacokinetic half-life of 0.09 hours, is currently in development to treat HF ​​(Novartis, 2014). Administration of serelaxin to healthy volunteers (NHVs) has been shown to increase RBF (Smith MC. et al., J. Am. Soc. Nephrol. 2006, 17, 3192-3197) and estimated GFR (Dahlke M. et al., J. Clin. Pharmacol.,2015, 55, 415-422). Increases in RBF were also observed in patients with stable compensated HF (Voors AA. et al., Cir. Heart Fail., 2014, 7, 994-1002). In large clinical trials, favorable changes in renal function deterioration, HF worsening, and less death were observed in patients with acutely decompensated HF (ADHF) in response to in-hospital 48-hour intravenous infusion of serelaxin (Teerlink JR. et al., Lancet, 2013, 381, 29-39), (Ponikowski P. et al., Eur Heart, 2014, 35, 431-441). Suggesting that chronic administration of serelaxin may provide sustained benefit to HF patients, improvements in renal function based on serum creatine levels were observed in scleroderma patients who received serelaxin continuously via subcutaneous pump for 6 months (Teichman SL. et al., Heart Fail. Rev., 2009, 14, 321-329). In addition to its therapeutic potential for treating HF, continuous subcutaneous administration of relaxin has also proven effective in various animal models of lung injury (Unemori EN. et al., J. Clin. Invet. 1996, 98, 2739-2745), kidney injury (Garber SL. et al., Kidney Int., 2001, 59, 876-882), and liver injury (Bennett RG., Liver Int., 2014, 34, 416-426).

[0009] In summary, a large body of evidence supports the role of relaxin-dependent agonism of RXFP1 in mediating adaptive changes that occur during mammalian pregnancy, and supports that these changes have favorable physiological effects and outcomes when relaxin is administered to HF patients. Further preclinical animal studies in various disease experiments of lung, kidney and liver damage provide evidence that relaxin may provide therapeutic benefits for multiple indications in addition to HF when administered chronically. More specifically, chronic administration of relaxin may benefit patients suffering from lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease) or liver disease (e.g., nonalcoholic steatohepatitis and portal hypertension). Summary of the Invention

[0010] The present invention provides novel substituted norbornyl compounds, their stereoisomers, tautomers, pharma- ceutically acceptable salts or solvates, and their analogs, that are useful as RXFP1 receptor agonists. The present invention also provides processes and intermediates for making the compounds of the present invention. The present invention also provides pharmaceutical compositions comprising a pharma- ceutically acceptable carrier and at least one compound of the invention, or a stereoisomer, tautomer, pharma- ceutically acceptable salt, or solvate thereof.

[0011] The compounds of the invention may be used, for example, in the treatment and / or prevention of heart failure, fibrotic diseases, and pulmonary diseases (e.g., idiopathic pulmonary fibrosis), renal diseases (e.g., chronic renal disease), or liver diseases (e.g., non-alcoholic steatohepatitis and portal hypertension). The compounds of the invention may be used in therapy. The compounds of the invention may be used for the manufacture of a medicament for the treatment and / or prevention of heart failure.

[0012] The compounds of the present invention may be used alone, in combination with other compounds of the present invention, or in combination with one or more, preferably one or two, other drugs. These and other features of the invention will be described in expanded form as the disclosure proceeds. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] The present invention encompasses compounds of formula (I), which are RXFP1 receptor agonists, compositions containing the compounds, and methods of using the compounds or compositions.

[0014] In a first aspect, the present invention relates to a compound of formula (I): [ka] [In formula: R 1 ,Haro,CN,C 1-7 Alkyl (0 to 3 R 6 ), C 2-7 Alkenyl (0 to 3 R 6 ), C 2-7 Alkynyl (0 to 3 R 6 ), C 3-6 Cycloalkyl (0 to 3 R 14 ), C 3-6 Cycloalkenyl (0 to 3 R 14 substituted with 0 to 3 R 14 substituted with), or 4- to 6-membered heterocyclyl (O, S(=O) p , N, and N 14a and 0 to 3 R 14 ) and R 2 is H or C 1-3 is alkyl; R 3 -NR a C(=O)R 5 , -NR a C(=O)(CR d R d ) 1-2 R 7 , or -NR a C(=O)NR a R 7and; R 4 ,Haro,CN,C 1-4 Alkyl (substituted with 0-5 halo substituents), -OH, -OC 1-4 Alkyl (substituted with 0-5 halo substituents), -S(=O) p R c or aryl; R 5 is C 1-8 Alkyl (0 to 4 R 11 ) or C 3-6 Cycloalkyl (0 to 4 R 8 and 0 to 2 R 9 ) and R 6 Halo, OH, C 3-6 cycloalkyl, or aryl; R 7 is an aryl (0 to 4 R 8 and 0 to 2 R 9 ) and R 8 -OR b and; R 9 is halo, CN, phenyl (0-3 R 10 and 0 to 2 R 11 substituted with), or 3- to 12-membered heterocyclyl (O, S(=O) p , N, and N 11a and 0 to 3 R 10 and 0 to 2 R 11 ) and R 10 is halo, CN, or C 1-4 is alkyl; R 11 is C 1-3 Alkyl (0 to 1 R 12 and 0 to 1 R 13 ), -OR b , -NR a R a , -NR a C(=O)R b , -NR aC(=O)OR b , -NR a C(=O)NR a R a , -NR a S(=O) p R c , -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , -C(=O)NR a S(=O) p R c , -OC(=O)R b , -S(=O) p R c , -S(=O) p NR a R a , C 3-10 Carbocyclyl (0 to 5 R e substituted with), 4- to 6-membered heterocyclyl (O, S(=O) p , N and NR 15 and 0 to 5 R e ) and R 11a is H or C 1-4 Alkyl (0 to 2 R e ) and R 12 is halo, -C(=O)OR b , -C(=O)NHR a , -C(=O)NHOR b , or C 1-4 alkyl (substituted with 0-3 halo or OH substituents); R 13 -OR b , -NR a R a , -NR a C(=O)R b , -NR a C(=O)OR b , -NR a S(=O) p R c , -NR a S(O) p NR a Ra , -OC(=O)NR a R a , -OC(=O)NR a OR b , -S(=O) p NR a R a , or -S(O) p R c and; R 14 ,Haro,CN,C 1-4 Alkyl (substituted with 0-3 halo substituents), -OC 1-4 Alkyl (substituted with 0-3 halo substituents), -(CH2) 0-3 -NR a R a , -(CH2) 0-3 -aryl (0 to 3 R e substituted with 0 to 3 R e substituted with -(CH2) 0-3 -3 to 12 membered heterocyclyl (O, S(=O) p and N; e ) and R 14a is H, C(=O)C 1-4 Alkyl, or C 1-3 alkyl(substituted with 0-3 aryl substituents substituted with 0-2 halo substituents); R 15 , H, C 1-3 is alkyl, or aryl; R 16 is C 1-3 Alkyl (0 to 1 R e ), -C(=O)R b , -C(=O)OR b , -C(=O)NR a R a , -C(=O)NR a S(=O) p R c , -OC(=O)R b , -S(=O) p R c , or -S(=O) pNR a R a and; R a , H, C 1-5 Alkyl (0 to 5 R e ), C 2-5 Alkenyl (0 to 5 R e ), C 2-5 Alkynyl (0 to 5 R e substituted with -(CH2) n -C 3-10 Carbocyclyl (0 to 5 R e substituted with -(CH2) n -3 to 12 membered heterocyclyl (O, S(=O) p and N; e or R a and R a and together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl (O, S(=O) p and N; e (which is replaced by); R b , H, C 1-5 Alkyl (0 to 5 R e ), C 2-5 Alkenyl (0 to 5 R e ), C 2-5 Alkynyl (0 to 5 R e substituted with -(CH2) n -C 3-10 Carbocyclyl (0 to 5 R e substituted with -(CH2) n -3 to 12 membered heterocyclyl (O, S(=O) p and N; e ) and R c is C 1-5 Alkyl (0 to 5 R e ), C 2-5 Alkenyl (0 to 5 Re ), C 2-5 Alkynyl (0 to 5 R e ), C 3-6 Carbocyclyl or 3- to 12-membered heterocyclyl (O, S(=O) p and N; R d H, -OR b , or C 1-5 Alkyl (0 to 5 R e ) and R e is halo, CN, =O, C 1-6 Alkyl (0 to 5 R g ), C 2-6 Alkenyl (0 to 5 R g ), C 2-6 Alkynyl (0 to 5 R g substituted with -(CH2) n -C 3-10 Carbocyclyl (0 to 5 R g substituted with -(CH2) n -3 to 12 membered heterocyclyl (O, S(=O) p and N; g substituted with -(CH2) n OR f , -C(=O)OR f , -C(=O)NR f R f , -NR f C(=O)R f , -S(=O) p R f , -NR f C(=O)OR f , -OC(=O)NR f R f , or -(CH2) n NR f R f and; R f , H, C 1-5 Alkyl, C 3-6 cycloalkyl, or aryl; or Rf and R f and together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl (O, S(=O) p and N; R g , halo, CN, OH, C 1-6 Alkyl, C 3-6 cycloalkyl, or aryl; n is 0, 1, 2, or 3; p is 0, 1, or 2] or a pharma- ceutically acceptable salt thereof.

[0015] In a second aspect within the first aspect, the present invention provides a compound of formula (II): [ka] [In formula: R 1 Halo, C 1-4 Alkyl (substituted with 0-4 halo substituents), C 3-6 cycloalkyl, or phenyl; R 2 is H; R 4 is halo or C 1-4 alkyl (substituted with 0-4 halo substituents); R 5 is C 3-6 Cycloalkyl (0 to 1 R 9 ) and R 9 is halo, CN, or phenyl (0-1 R 10 and 0 to 1 R 11 ), [ka] and; R 10 is halo, CN, or C 1-4 is alkyl; R 11 -OH, -OC1-4 Alkyl, or -C(=O)OR b and; R 11a is H or C 1-3 is alkyl; R a is H or C 1-4 is alkyl; R b is H or C 1-4 is alkyl] or a pharma- ceutically acceptable salt thereof.

[0016] In a third aspect within the scope of the first to second aspects, the present invention provides a compound of formula (II): [ka] [In formula: R 1 Halo, C 1-4 Alkyl (substituted with 0-4 halo substituents), C 3-6 cycloalkyl, or phenyl; R 2 is H; R 4 is halo or C 1-4 alkyl (substituted with 0-4 halo substituents); R 5 is C 1-7 Alkyl (0 to 1 R 11 ) and R 11 -OR b , -C(=O)R b , -C(=O)OR b or -C(=O)NR a R a and; R a is H or C 1-4 is alkyl; R b is H or C 1-4 is alkyl] or a pharma- ceutically acceptable salt thereof.

[0017] In a fourth aspect within the first aspect, the present invention provides a compound of formula (III): [ka] [In formula: R 1 Halo, C 1-4 Alkyl (substituted with 0-4 halo substituents), C 3-6 cycloalkyl, or phenyl; R 2 is H; R 4 is halo or C 1-4 alkyl (substituted with 0-4 halo substituents); R 7 is aryl (0 to 1 R 8 and 0 to 1 R 9 ) and R 8 -OR b and; R 9 is halo, CN, or phenyl (0-3 R 10 and 0 to 2 R 11 ) and R 10 ,Haro,CN,C 1-4 Alkyl, -OH, or -OC 1-4 is alkyl; R 11 -OR b OR -C(=O)OR b and; R a is H or C 1-4 is alkyl; R b , H, C 1-4 alkyl, or phenyl; R d is -OH or -OC 1-4 is alkyl] or a pharma- ceutically acceptable salt thereof.

[0018] In a fifth aspect within the first aspect, the present invention provides a compound of formula (IV): [ka] [In formula: R 1 Halo, C 1-4 Alkyl (substituted with 0-4 halo substituents), C 3-6 cycloalkyl, or phenyl; R 2 is H; R 4 is halo or C 1-4 alkyl (substituted with 0-4 halo substituents); R 7 is aryl (0 to 1 R 8 and 0 to 1 R 9 ) and R 8 Ha-OC 1-4 alkyl (substituted with 0-5 halo or OH substituents); R 9 is halo, CN, or phenyl (0-3 R 10 and 0 to 2 R 11 ) and R 10 ,Haro,CN,C 1-4 Alkyl, -OH, or -OC 1-4 is alkyl; R 11 -OR b OR -C(=O)OR b and; R a is H or C 1-4 is alkyl; R b , H, C 1-4 alkyl, or phenyl] or a pharma- ceutically acceptable salt thereof.

[0019] In the compounds of formula (I), R 1 , R 2 , R 3 , R 4 , R5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 11a , R 12 , R 13 , R 14 , R 14a , R 15 , R a , R b , R c , R d , R e , R f , and R g Any of the exemplary ranges for a variable substituent, including, may be used independently of any other range for a variable substituent. Thus, the invention encompasses combinations of different embodiments.

[0020] Unless otherwise specified, these terms have the following meanings: "Halo" includes fluoro, chloro, bromo and iodo. "Alkyl" or "alkylene" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, "C1-C 10 Alkyl" or "C 1-10 "Alkyl" (or alkylene) is any of the following alkyl groups: C1, C2, C3, C4, C5, C6, C7, C8, C9, and C 10It is intended to include alkyl groups. Additionally, for example, "C1-C6 alkyl" or "C1-C6 alkyl" refers to an alkyl having 1 to 6 carbon atoms. The alkyl group can be unsubstituted or substituted such that at least one hydrogen is replaced with another chemical group. Exemplary alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), and pentyl (e.g., n-pentyl, isopentyl, neopentyl). When "C0 alkyl" or "C0 alkylene" is used, it is intended to indicate a direct bond. "Alkyl" also includes deuterated alkyls such as CD3.

[0021] "Alkenyl" or "alkenylene" is intended to include a hydrocarbon chain in either a straight or branched configuration having one or more, preferably one to three, carbon-carbon double bonds, which may occur at any stable point along the chain. For example, "C2-C6 alkenyl" or "C 2-6 "Alkenyl" (or alkenylene) is intended to include C2, C3, C4, C5, and C6 alkenyl groups, such as ethenyl, propenyl, butenyl, pentenyl, and hexenyl. "Alkynyl" or "alkynylene" is intended to include a hydrocarbon chain in either a straight or branched configuration having one or more, preferably one to three, carbon-carbon triple bonds, which may occur at any stable point along the chain. For example, "C2-C6 alkynyl" or "C 2-6 "Alkynyl" (or alkynylene) is intended to include C2, C3, C4, C5, and C6 alkynyl groups, such as ethynyl, propynyl, butynyl, pentynyl, and hexynyl.

[0022] "Carbocycle", "carbocyclyl", or "carbocyclic moiety" is intended to mean any stable 3-, 4-, 5-, 6-, 7-, or 8-membered monocyclic or bicyclic, or 7-, 8-, 9-, 10-, 11-, 12-, or 13-membered bicyclic or tricyclic hydrocarbon ring, any of which may be saturated, partially unsaturated, unsaturated or aromatic. Examples of such carbocyclyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, anthracenyl, and tetrahydronaphthyl (tetralin). As noted above, bridged rings are also included in the definition of carbocyclyl (e.g., [2.2.2]bicyclooctane). A bridged ring occurs when one or more carbon atoms link two non-adjacent carbon atoms. Preferred bridges are one or two carbon atoms. It should be noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge. When the term "carbocyclyl" is used, it is intended to include "aryl", "cycloalkyl", and "spirocycloalkyl". Preferred carbocyclyls, unless otherwise specified, are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, and indanyl.

[0023] "Cycloalkyl" is intended to mean a cyclized alkyl group, including monocyclic, bicyclic or polycyclic ring systems. "C3-C7 cycloalkyl" or "C 3-7"Cycloalkyl" is intended to include C3, C4, C5, C6, and C7 cycloalkyl groups. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Non-limiting examples of polycyclic cycloalkyls include 1-decalinyl, norbornyl, and adamantyl. "Spirocycloalkyl" is intended to mean a hydrocarbon bicyclic ring system in which both rings are connected through a single atom. The rings can be of different sizes and nature or of the same size and nature. Examples include spiropentane, spirohexane, spiroheptane, spirooctane, spirononane, or spirodecane.

[0024] "Bicyclic carbocyclyl" or "bicyclic carbocyclic group" is intended to mean a stable 9- or 10-membered carbocyclic ring system containing two fused rings and consisting of carbon atoms. Of the two fused rings, one ring is a benzo ring fused to another ring, which is a 5- or 6-membered carbocyclic ring that is saturated, partially unsaturated, or unsaturated. A bicyclic carbocyclic group may be attached to its pendant group at any carbon atom that results in a stable structure. The bicyclic carbocyclic groups described herein may be substituted on any carbon, provided that the resulting compound is stable. Examples of bicyclic carbocyclic groups include, but are not limited to, naphthyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and indanyl.

[0025] An "aryl" group refers to a monocyclic or polycyclic aromatic hydrocarbon, including, for example, phenyl, naphthyl, and phenanthranyl. Aryl moieties are well known and are described, for example, in Lewis, RJ (ed.), Hawley's Condensed Chemical Dictionary, 13th Edition, John Wiley & Sons, Inc., New York (1997). "Benzyl" means a methyl group in which one of the hydrogen atoms is replaced by a phenyl group, where the phenyl group is optionally substituted with 1 to 5 groups, preferably 1 to 3 groups.

[0026] "Heterocycle", "heterocyclyl" or "heterocyclic ring" is intended to mean a stable 3-, 4-, 5-, 6-, or 7-membered mono- or bicyclic, or 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered polycyclic heterocyclic ring that is saturated, partially unsaturated, or fully unsaturated and contains carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S, and is intended to include any polycyclic group in which any of the above heterocyclic rings are fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., [ka] and S(O) p where p is 0, 1 or 2). The nitrogen atom may be substituted or unsubstituted (i.e., N or NR, where R, as defined, is H or another substituent). A heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in a heterocyclyl may optionally be quaternized. It is preferred that if the total number of S and O atoms in a heterocyclyl exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in a heterocyclyl is at most 1. Bridged rings are also included in the definition of heterocyclyl. When the term "heterocyclyl" is used, it is intended to include heteroaryl.

[0027] Examples of heterocyclyl include, but are not limited to, acridinyl, azetidinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetra ...4aH-carbazolyl, 4aH-carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 4aH-carbazolyl, 4aH-carbazolyl, 4aH-carbazolyl, 4aH-carbazolyl, 4aH-carbazolyl, 4aH-carbazolyl, 4aH-carbazolyl, tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, imidazolopyridinyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolopyridinyl, isoxazolyl, isoxazolopyridinyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl aryl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolopyridinyl, oxazolidinylperimidinyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, phteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, Pyrazolinyl, pyrazolopyridinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2-pyrrolidonyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrazolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thiazolopyridinyl, thienothiazolyl, thienoxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl. Also included are fused ring and spiro compounds containing the above heterocyclyls.

[0028] A "bicyclic heterocycle", "bicyclic heterocyclyl" or "bicyclic heterocyclic group" is intended to mean a stable 9- or 10-membered heterocyclic ring system containing two fused rings and consisting of carbon atoms and 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S. One of the two fused rings is a 5- or 6-membered monocyclic aromatic ring consisting of a 5-membered heteroaryl ring, a 6-membered heteroaryl ring or a benzo ring, each fused to a second ring. The second ring is a saturated, partially unsaturated or unsaturated 5- or 6-membered polycyclic ring consisting of a 5-membered heterocyclyl, a 6-membered heterocyclyl or a carbocyclyl (with the proviso that if the second ring is a carbocyclyl then the first ring is a ring other than benzo).

[0029] Bicyclic heterocyclic group may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.Bicyclic heterocyclic group described herein may be substituted on carbon or nitrogen atom if the resulting compound is stable.If the total number of S and O atoms in heterocyclyl is more than 1, then it is preferred that these heteroatoms are not adjacent to each other.It is preferred that the total number of S and O atoms in heterocyclyl is at most 1.

[0030] Examples of bicyclic heterocyclic groups include, but are not limited to, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, indolyl, isoindolyl, indolinyl, 1H-indazolyl, benzimidazolyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydroquinolinyl, 2,3-dihydrobenzofuranyl, chromanyl, 1,2,3,4-tetrahydroquinoxalinyl, and 1,2,3,4-tetrahydroquinazolinyl.

[0031] "Heteroaryl" is intended to mean stable monocyclic and polycyclic aromatic hydrocarbons containing at least one heteroatom ring member, such as sulfur, oxygen, or nitrogen. Heteroaryl groups include, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, benzodioxolanyl, and benzodioxane. Heteroaryl groups may be substituted or unsubstituted. Nitrogen atoms may be substituted or unsubstituted (i.e., N or NR, where R is H or another substituent, as defined). The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., [ka] and S(O) p where p is 0, 1 or 2).

[0032] As referred to herein, the term "substituted" means that at least one hydrogen atom is replaced with a group other than hydrogen, provided that normal valence is maintained and the replacement results in a stable compound. If the substituent is keto (i.e., =O), then two hydrogens on the atom are replaced. Keto substituents are not present in aromatic moieties. If a ring system (e.g., a carbocyclic or heterocyclic ring system) is likely to be substituted with a carbonyl group or double bond, the carbonyl group or double bond is intended to be part of the ring (i.e., within the ring). As used herein, a ring double bond is a double bond formed between two adjacent ring atoms (e.g., C=C, C=N, or N=N).

[0033] Where there are nitrogen atoms (e.g., amines) on the compounds of the invention, these can be converted to N-oxides by treatment with an oxidizing agent (e.g., mCPBA and / or hydrogen peroxide) to give other compounds of the invention. Thus, the depicted and claimed nitrogen atoms are the same as the depicted nitrogen and its N-oxide. [ka] It is believed that this applies to both the amide and its derivatives.

[0034] When any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0 to 3 R groups, then the group may be optionally substituted with up to three R groups, where R at each occurrence is independently selected from the definitions of R. Also, combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.

[0035] When a bond to a substituent is shown across a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom to which such substituent is attached to the remainder of the compound of a given formula, then such substituent may be bonded through any atom of such substituent. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.

[0036] The present invention encompasses all pharma- ceutically acceptable salt forms of the compounds. Pharmaceutically acceptable salts are those in which the counterion does not contribute significantly to the physiological activity or toxicity of the compound and acts as a pharmaceutical equivalent itself. These salts can be prepared using common organic techniques and commercially available reagents. Some forms of anionic salts include acetate, acetositolate, besylate, bromide, chloride, citrate, fumarate, glucuronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xynofoate. Some forms of cationic salts include ammonium, aluminum, vanzatin, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc.

[0037] Throughout the specification and the appended claims, a given chemical formula or name encompasses all such stereoisomers and optical isomers, as well as racemates, when isomers exist. Unless otherwise specified, all chiral (enantiomers and diastereomers) and racemates are within the scope of the present invention. Enantiomers and diastereomers are examples of stereoisomers. The term "enantiomer" refers to one of a pair of molecular species that are mirror images of each other and are non-superimposable. The term "diastereomer" refers to a stereoisomer that is not a mirror image. The term "racemate" or "racemic mixture" refers to a composition consisting of equimolar amounts of two enantiomeric species, where the composition lacks optical activity.

[0038] The present invention encompasses all tautomers, atropisomers and rotamers of the compounds. All processes used to prepare compounds of the present invention and intermediates made along the way are considered to be part of the present invention. The symbols "R" and "S" represent the configuration of substituents around a chiral carbon atom. The isomeric descriptors "R" and "S" are used herein to indicate the atomic configuration relative to a core molecule and are intended to be used as defined in the literature (IUPAC Recommendations 1996, Pure and Applied Chemistry, 68:2193-2222 (1996)).

[0039] The term "chiral" refers to the structural characteristic of a molecule that makes it impossible to superimpose it on its mirror image. The term "homochiral" refers to the state of being enantiomerically pure. The term "optically active" refers to the angle that a homochiral molecule or a nonracemic mixture of chiral molecules rotates the plane of polarized light.

[0040] The present invention is intended to include all isotopes of atoms present in a compound. Isotopes include those atoms having the same atomic number but different mass numbers. By way of example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon are 13 C and 14 The isotopically labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art, or by methods similar to those described herein, substituting an appropriately isotopically labeled reagent for an unlabeled reagent used in other methods. Such compounds may have a variety of potential uses, for example, as probes or reagents in determining biological activity. In the case of stable isotopes, such compounds may have the potential to advantageously modify biological, pharmacological, or pharmacokinetic properties.

[0041] biological methods RXFP1 cyclic adenosine monophosphate (cAMP) assay Human embryonic kidney cells 293 (HEK293 cells) and HEK293 cells stably expressing human RXFP1 were cultured in MEM medium supplemented with 10% qualified FBS and 300 μg / ml hygromycin (Life Technologies). Cells were dissociated and suspended in assay buffer. Assay buffer was HBSS buffer (with calcium and magnesium) containing 20 mM HEPES, 0.05% BSA, and 0.5 mM IBMX. Cells (3000 cells per well except for HEK293 cells stably expressing human RXFP1, which had 1500 cells per well) were added to 384-well Proxiplates (Perkin-Elmer). Cells were immediately treated with test compounds in DMSO (2% final) at final concentrations ranging from 0.010 nM to 50 μM. Cells were incubated at room temperature for 30 min. Intracellular cAMP levels were measured using the HTRF HiRange cAMP Assay Reagent Kit (Cisbio) according to the manufacturer's instructions. Solutions of cryptate-conjugated anti-cAMP and d2 fluorescently labeled cAMP were prepared separately in the supplied lysis buffer. After the end of the reaction, cells were lysed with equal volumes of d2-cAMP and anti-cAMP solutions. After incubation for 1 h at room temperature, time-resolved fluorescence intensity was measured at an excitation wavelength of 400 nm and dual emission wavelengths of 590 and 665 nm using an Envision (Perkin-Elmer). A calibration curve was constructed by plotting the ratio of the fluorescence intensity at 665 nm emission to the fluorescence intensity at 590 nm emission versus cAMP concentration using external cAMP reagents at concentrations ranging from 2.7 μM to 0.1 pM. The potency and activity of compounds in inhibiting cAMP production were then measured by plotting cAMP levels versus compound concentration and fitting them to a four-parametric logistic equation.

[0042] The examples disclosed below were tested in the human RXFP1 (hRXFP1) HEK293 cAMP assay described above and found to have agonistic activity. Table 1 shows the EC50 values ​​in the hRXFP1 HEK293 cAMP assay measured for the examples. 50 Enumerate values.

[0043] Table 1 [Table 1]

[0044] Pharmaceutical Compositions and Methods of Use The compounds of formula (I) are RXFP1 receptor agonists and may find use in the treatment of medical indications such as heart failure (e.g., HFREF and HFpEF), fibrotic diseases, and associated diseases such as pulmonary disease (e.g., idiopathic pulmonary fibrosis or pulmonary hypertension), renal disease (e.g., chronic renal disease), or liver disease (e.g., nonalcoholic steatohepatitis, and portal hypertension). The compounds of formula (I) may also be used to treat disorders that are the result or cause of decreased arterial stiffness, arterial elasticity, decreased arterial compliance and distensibility, including hypertension, renal disease, peripheral arterial disease, carotid artery disease, and cerebrovascular disease (i.e., stroke and dementia), diabetes, microvascular disease resulting in end-organ damage, coronary artery disease, and heart failure. The compounds described herein may also be used to treat preeclampsia.

[0045] Another aspect of the present invention is a pharmaceutical composition comprising a compound of formula (I) and a pharma- ceutically acceptable carrier. Another aspect of the present invention is a pharmaceutical composition comprising a compound of formula (I) and a pharma- ceutically acceptable carrier for treating a relaxin-related disorder. Another aspect of the present invention is a method of treating a relaxin-associated disease, comprising administering an effective amount of a compound of formula (I).

[0046] Another aspect of the present invention is a method for treating cardiovascular disease, comprising administering to a patient in need thereof an effective amount of a compound of formula (I). Another aspect of the present invention is a method for treating heart failure, comprising administering to a patient in need thereof an effective amount of a compound of formula (I). Another aspect of the present invention is a method of treating fibrosis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I).

[0047] Another aspect of the present invention is a method for treating a disease associated with fibrosis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I). Another aspect of the present invention is a method of treating idiopathic pulmonary fibrosis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I). Another aspect of the present invention is a method of treating idiopathic pulmonary fibrosis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I).

[0048] Another aspect of the present invention is a method for treating or preventing renal failure, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I). Another aspect of the present invention is a method of improving, stabilizing or restoring renal function in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I). Another aspect of the present invention is a method of treating liver disease, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I).

[0049] Another aspect of the present invention is a method for treating non-alcoholic steatohepatitis and portal hypertension, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I). Another aspect of the present invention resides in the use of compounds of formula (I) for the prevention and / or treatment of relaxin-related disorders. Another aspect of the present invention resides in a compound of formula (I) for use in the prevention and / or treatment of relaxin-related disorders.

[0050] Unless otherwise stated, the following terms have the meanings indicated. The term "patient" or "subject" refers to any human or non-human organism that may benefit from treatment with RXFP1 agonist, as substituted by those skilled in the art.Exemplary subjects include humans of any age who have risk factors for cardiovascular disease.Common risk factors include, but are not limited to, age, sex, weight, family history, sleep apnea, alcohol or tobacco use, physical inactivity, arrhythmia, or symptoms of insulin resistance, such as acanthosis nigricans, hypertension, dyslipidemia, or polycystic ovarian syndrome (PCOS).

[0051] "Treating" or "treatment", as will be understood by those of skill in the art, extends to the treatment of a condition and includes: (a) inhibiting the condition, i.e., arresting its onset; (b) alleviating the condition, i.e., causing regression of the condition; and / or (c) preventing the onset of the disease in a mammal, particularly when such mammal is predisposed to suffering from the condition but has not yet been diagnosed as such.

[0052] "Preventing" or "prevention", as understood by those skilled in the art, covers prophylactic treatment (i.e., prevention and / or risk reduction) of subclinical conditions aimed at reducing the probability of occurrence of a clinical condition. Patients are selected for prophylactic treatment based on factors known to increase the risk of suffering from a clinical condition compared to the general population. "Preventive" therapy can be divided into (a) primary prevention and (b) secondary prevention. Primary prevention is defined as treatment in subjects who have not yet exhibited a clinical condition, whereas secondary prevention is defined as preventing the secondary onset of the same or similar clinical condition. "Risk reduction" or "risk reduction" covers therapy that reduces the incidence of a clinical condition. Primary and secondary prevention therapies are themselves examples of risk reduction.

[0053] "Therapeutically effective amount" is intended to include an amount of a compound of the invention that is effective when administered alone or in combination with other agents to treat a disorder, as understood by those skilled in the art. When applied to a combination, the term refers to the combined amount of active ingredients that results in a prophylactic or therapeutic effect, whether administered in combination, sequentially, or simultaneously.

[0054] "Cardiovascular system disorders" or "cardiovascular disorders" include, for example, the following disorders: hypertension (high blood pressure), peripheral vascular and cardiovascular disorders, coronary heart disease, stable and unstable angina, heart attack, myocardial insufficiency, abnormal heart rhythm (or arrhythmia), persistent ischemic dysfunction ("hibernating myocardium"), transient post-ischemic dysfunction ("stunned myocardium"), heart failure, impaired peripheral blood flow, acute coronary syndromes, heart failure, myocardial disease (cardiomyopathy), myocardial infarction, and vascular diseases (vascular disease).

[0055] "Heart failure" includes both acute and chronic manifestations of heart failure, as well as progressive heart failure, cardiac-renal syndrome following acute heart failure, heart failure with renal dysfunction, chronic heart failure, chronic heart failure with intermediate ejection fraction (HFmEF), compensated heart failure, decompensated heart failure, right ventricular failure, left ventricular failure, global failure, ischemic cardiomyopathy, dilated cardiomyopathy, heart failure secondary to congenital heart injury, valvular heart disease, heart failure secondary to valvular heart disease, mitral stenosis, mitral regurgitation, aortic stenosis, aortic regurgitation, tricuspid stenosis, tricuspid regurgitation, pulmonary stenosis, aortic regurgitation, complex These include more specific or associated types of the disease such as heart failure associated with valvular heart disease, myocardial inflammation (myocarditis), chronic myocarditis, acute myocarditis, viral myocarditis, diabetic heart failure, alcoholic cardiomyopathy, heart failure associated with cardiac reservoir disease, diastolic heart failure, systolic heart failure, acute worsening heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), chronic heart failure with reduced ejection fraction (HFrEF), chronic heart failure with preserved ejection fraction (HFpEF), stenosis after myocardial remodeling, hypertension, pulmonary hypertension and pulmonary arterial hypertension.

[0056] "Fibrotic disorders" encompasses, inter alia, the following diseases and disorders characterized by fibrogenesis, including liver fibrosis, cirrhosis, NASH, pulmonary fibrosis, myocardial fibrosis, endocardial fibrosis, nephropathy, glomerulonephritis, renal interstitial fibrosis, fibrotic disorders due to diabetes, myelofibrosis and similar fibrotic disorders, scleroderma morphea, keloids, hypertrophic scars (even after surgery), nevi, diabetic retinopathy, proliferative vitreoretinopathy, and disorders of connective tissue (e.g., sarcoidosis). Relaxin-related disorders include, but are not limited to, cardiovascular and fibrotic disorders.

[0057] The compounds of the present invention can be administered by any suitable means, for example, orally, such as tablets, capsules (each of which includes sustained release or time release formulations), pills, powders, granules, elixirs, tinctures, suspensions (nano-suspensions, micro-suspensions, spray-dried dispersions), syrups, and emulsions; sublingually; buccal; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection or infusion techniques (e.g., as a sterile injectable aqueous or non-aqueous solution or suspension); nasally, including administration to the nasal membranes, such as by inhalation spray; topically, such as in the form of creams or ointments; or rectally, such as in the form of suppositories.The compounds can be administered alone, but will generally be administered together with a pharmaceutical carrier selected based on the selected route of administration and standard pharmaceutical practice.

[0058] "Pharmaceutical composition" refers to the composition comprising the compound of the present invention in combination with at least one additional pharmaceutical acceptable carrier. "Pharmaceutical acceptable carrier" refers to the medium generally accepted in the art for delivering biologically active agent to animals, particularly mammals, including adjuvants, excipients or vehicles such as diluents, preservatives, fillers, flow regulators, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavorings, perfumes, antibacterial agents, antifungal agents, lubricants and dispersants, depending on the characteristics of administration mode and dosage form.

[0059] Pharmaceutically acceptable carriers are formulated according to many factors well within the scope of a person skilled in the art. These factors include, but are not limited to, the type and nature of the active agent to be formulated; the subject to which the composition containing the drug is to be administered; the intended route of administration of the composition; and the targeted therapeutic indication. Pharmaceutically acceptable carriers include both aqueous and non-aqueous liquid media, as well as various solid and semi-solid dosage forms. Such carriers can include many different components and additives in addition to the active agent, and such additional components are incorporated into the formulation for various reasons, such as stabilization of the active agent, binders, etc., as is well known to those skilled in the art. A description of suitable pharmacologic acceptable carriers and the factors involved in their selection can be found in a variety of readily available sources, such as, for example, Allen, LV et al., Remington: The Science and Practice of Pharmacy (2 Volumes), 22nd Edition, Pharmaceutical Press (2012).

[0060] The administration regimen of the compounds of the invention will, of course, vary according to known factors such as the pharmacological properties of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; type of concurrent treatment; frequency of treatment; route of administration; the renal and hepatic function of the patient; and the desired effect.

[0061] As a general guideline, the daily oral dose of each active ingredient, when used to obtain the indicated effects, will be in the range of about 0.01 to about 5000 mg per day, preferably about 0.1 to about 1000 mg per day, and most preferably about 0.1 to about 250 mg per day. For intravenous administration, the most preferred dose will be in the range of about 0.01 to about 10 mg / kg / min at a constant rate infusion. The compounds of the present invention may be administered in a single daily dose, or the total daily dose may be administered in divided doses two, three or four times daily.

[0062] The compounds are typically administered in admixture with a suitable pharmaceutical diluent, excipient, or carrier (collectively referred to herein as pharmaceutical carriers) appropriately selected for the intended form of administration, e.g., oral tablets, capsules, elixirs, and syrups, and consistent with conventional pharmaceutical practice.

[0063] A dosage form (pharmaceutical composition) suitable for administration may contain about 1 milligram to about 2000 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions, the active ingredient will usually be incorporated in an amount of about 0.1% by weight-95% by weight based on the total weight of the composition. A typical capsule for oral administration contains at least one compound of the present invention (250 mg), lactose (75 mg), and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and filled into a No. 1 gelatin capsule. A typical injectable formulation is produced by placing at least one compound of the present invention (250 mg) in a vial under aseptic conditions, freeze-drying it under aseptic conditions, and sealing it. At the time of use, the contents of the vial are mixed with 2 mL of physiological saline to produce an injectable formulation.

[0064] The compounds of the present invention may be utilized in combination with other suitable therapeutic agents useful for the treatment of diseases or disorders, including anti-atherosclerotic agents, antilipidemic agents, anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemia agents, anti-thrombotic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenosis agents, anti-pancreatic agents, lipid lowering agents, anorexic agents, memory enhancing agents, anti-dementia agents, cognition enhancing agents, appetite suppressants, heart failure therapeutic agents, peripheral arterial disease therapeutic agents, malignant tumor therapeutic agents, and anti-inflammatory agents.

[0065] Additional therapeutic agents include ACE inhibitors, beta-blockers, diuretics, mineralocorticoid receptor antagonists, ryanodine receptor modulators, SERCA2a activators, renin inhibitors, calcium channel blockers, adenosine A1 receptor agonists, partial adenosine A1 receptors, dopamine beta-hydroxylase inhibitors, angiotensin II receptor antagonists, angiotensin II receptor antagonists biased towards agonism to select cell signaling pathways, angiotensin II receptor antagonists combinations of sedatives and neprilysin enzyme inhibitors, neprilysin enzyme inhibitors, soluble guanylate cyclase activators, myosin ATPase activators, rho-kinase 1 inhibitors, rho-kinase 2 inhibitors, apelin receptor agonists, nitroxyl-donating compounds, calcium-dependent kinase II inhibitors, antifibrogenic agents, galectin-3 inhibitors, vasopressin receptor antagonists, FPR2 receptor modulators, natriuretic peptide receptor agonists, transient receptor potential vanilloid-4 channel blockers, antiarrhythmic agents, tentative (I f ) "Funny current" channel s blockers, nitrates, digitalis compounds, cardiac inotropes and β-receptor agonists, cell membrane resealing agents, e.g., poloxamer 188, antihyperlipidemic agents, plasma HDL-raising agents, antihypercholesterolemic agents, cholesterol biosynthesis inhibitors (HMG CoA reductase inhibitors), LXR agonists, FXR agonists, probucol, raloxifene, nicotinic acid, niacinamide, cholesterol absorption inhibitors, bile acid sequestrants, anion exchange resins, quaternary amines, cholestyramine, colestipol, low density lipoprotein receptor inducers, clofibrate, fenofibrate, bezafibrate, ciprofibrate, gemfibrizol, vitamin B6, vitamin B12, antioxidant vitamins, antidiabetic agents, platelet aggregation inhibitors, fibrinogen receptor antagonists, aspirin and fibric acid derivatives, PCSK9 inhibitors, aspirin, and P2Y12 inhibitors such as clopidogrel.

[0066] Additional therapeutic agents also include nintedanib, pirfenidone, LPA1 antagonists, LPA1 receptor antagonists, GLP1 analogs, traloquinucab (IL-13, AstraZeneca), vismodegib (hedgehog antagonist, Roche), PRM-151 (Pentraxin-2, TGF beta-1, Promedior), SAR-156597 (Bispecific Mab IL-4 & IL-13, Sanofi), simtuzumab (anti-lysyl oxidase-like 2 (anti-LOXL2) antibody, Gilead), CKD-942, PTL-202 (PDE inhibitor / pentoxifylline / NAC oral controlled release, Pacific These agents may also include omipalisib (oral PI3K / mTOR inhibitor, from GSK), IW-001 (oral solution, modified bovine collagen V, from ImmuneWorks), STX-100 (integrin alpha V / beta-6 ant, from Stromedix / Biogen), Actimun (IFN gamma), PC-SOD (midismase; inhalant, from LTT Bio-Pharma / CKD Pharm), lebrikizumab (anti-IL-13 SC humanized mAb, from Roche), AQX-1125 (SHIP1 activator, from Aquinox), CC-539 (JNK inhibitor, from Celgene), FG-3019 (from FibroGen), SAR-100842 (from Sanofi), and obeticholic acid (OCA or INT-747, from Intercept).

[0067] The other therapeutic agents described above, when utilized in combination with the compounds of the present invention, may be used, for example, in those amounts set forth in the Physicians' Desk Reference, as in the patents mentioned above, or in amounts otherwise determined by one of skill in the art.

[0068] There is a possibility of chemical interaction between the combined active ingredients, especially when provided as a single dosage unit. For this reason, when the compound of the present invention and another therapeutic agent are combined in a single dosage unit, the active ingredients are combined in a single dosage unit, but are formulated so that the physical contact between the active ingredients is minimized (i.e., reduced). For example, one of the active ingredients may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also to adjust the release of one of the ingredients in the digestive tract, so that one of the ingredients is not released in the stomach, but rather in the intestine. Also, one of the active ingredients may be coated with a material that affects the sustained release through the entire digestive tract and further serves to minimize the physical contact between the combined active ingredients. Furthermore, the sustained release ingredient may be further enteric coated so that the release of this ingredient occurs only in the intestine. Yet another solution would involve formulating the active ingredients into a combination product in which one component is coated with a sustained release and / or enteric polymer and the other component is also coated with a polymer such as a low viscosity grade of hydroxypropylmethylcellulose (HPMC) or other suitable material known in the art to further separate the active ingredients. The polymer coating serves to form an additional barrier to interaction with the other component.

[0069] The compounds of the present invention are also useful as control or control compounds, for example as quality control or control, in tests or assays involving RXFP1. Such compounds may be provided, for example, in commercially available kits for use in pharmaceutical research involving RXFP1. For example, the compounds of the present invention may be used as controls in assays to compare their known activity with compounds of unknown activity. This allows the experimental researcher to ensure that the assay has been performed properly, and provides a basis for comparison, especially when the test compound is a derivative of the control compound. When developing new assays or protocols, the compounds of the present invention may be used to test their effectiveness. The compounds of the present invention may also be used in diagnostic assays involving RXFP1.

[0070] The present invention also encompasses articles of manufacture. As used herein, articles of manufacture includes, but is not limited to, kits and packages. The articles of manufacture of the present invention include (a) a first container; (b) a pharmaceutical composition contained within the first container, the composition comprising a first therapeutic agent comprising a compound of the present invention or a pharma- ceutically acceptable salt form thereof; and (c) a package insert stating that the pharmaceutical composition can be used for the treatment of dyslipidemia and its sequelae. In another embodiment, the package insert states that the pharmaceutical composition can be used in combination (as described above) with a second therapeutic agent for the treatment of dyslipidemia and its sequelae. The articles of manufacture may further include (d) a second container, where components (a) and (b) are contained within the second container and component (c) is placed inside or outside the second container. Placed within the first and second containers means that each container holds items within its boundaries.

[0071] A first container is a container used to hold a pharmaceutical composition. This container can be for manufacturing, storing, and / or selling individually / in bulk. It is intended that the first container also encompasses bottles, jars, vials, flasks, syringes, tubes (e.g., for cream formulations), or any other container used to manufacture, hold, store, or distribute a pharmaceutical product.

[0072] The second container is a container that is used to hold the first container and, optionally, the package insert. Examples of the second container include, but are not limited to, boxes (e.g., cardboard boxes or plastic boxes), crates, cartons, bags (e.g., paper bags or plastic bags), pouches and sacks. The package insert can be physically attached to the outside of the first container via tape, adhesive, staples, or another attachment means, or can be fastened to the inside of the second container without being attached to the first container by any physical means. Alternatively, the package insert is located on the outside of the second container. When located on the outside of the second container, it is preferable that the package insert is physically attached via tape, adhesive, staples, or another attachment means. Alternatively, the package insert can be adjacent to or in contact with the outside of the second container without being physically attached.

[0073] The package insert is a label, tag, marker, etc. that describes information about the pharmaceutical composition that is located in the first container. The information described will usually be determined by the regulatory agency (e.g., the United States Food and Drug Administration) governing the geographic area in which the product is intended to be sold. The package insert preferably specifically describes the indications for which the pharmaceutical composition is approved. The package insert may be made of any material that allows a person to read the information contained therein or thereon. Preferably, the package insert is a printable material (e.g., paper, plastic, cardboard, wheels, adhesive-backed paper or plastic, etc.) on which the desired information is formed (e.g., printed or coated).

[0074] chemical method The compounds of the invention can be made by a variety of methods known in the art, including those described in the schemes below and in the specific embodiments section. The structure and variable numbering shown in the synthetic schemes is different from, and should not be confused with, the structure or variable numbering in the claims or the remainder of the specification. The variables in the schemes are only meant to illustrate how to make some of the compounds of the invention.

[0075] The present disclosure is not limited to the illustrated embodiments, which are to be considered in all respects as illustrative and not restrictive, and all changes which come within the meaning and range of equivalency of the claims are thus intended to be embraced.

[0076] It will also be appreciated that another major consideration in planning any synthetic route in this field is the judicious selection of protecting groups used to protect reactive functionalities present in the compounds described in this invention. An authoritative text describing the many options for those skilled in the art is Greene, TW et al., Protecting Groups in Organic Synthesis, 4th Edition, Wiley (2007).

[0077] Abbreviations are: "1x" for 1, "2x" for 2, "3x" for 3, "°C" for Celsius, "aq" for aqueous, "eq" or "equiv" for equivalent, "g" for gram, "mg" for milligram, "L" for liter, "mL" for milliliter, "μL" for microliter, "N" for normal, "M" for mole, "nM" for nanomole, "pM" for picomole, "mol" for mole, "mmol" for millimole, "min" for minute, "h" for hour, "rt" for room temperature, "RT" for retention time, "atm" for atmosphere, "psi" for pounds per square inch, "conc." for concentrated, "aq" for aqueous, "sat." for saturated, "MW" for molecular weight, and "MS" or "Mass" for mass spectrometry. Spec," for Electron Spray Ionization or Mass Spectroscopy, "ESI," for Liquid Chromatography-Mass Spectroscopy, "LC-MS," for Liquid Chromatography-Mass Spectroscopy, "HPLC," for High Pressure Liquid Chromatography, "RP HPLC," for Reverse Phase HPLC, "NMR," for Nuclear Magnetic Resonance Spectroscopy, "SFC," for Supercritical Fluid Chromatography, and " 1 "H", "δ" for delta, "s" for singlet, "d" for doublet, "t" for triplet, "q" for quartet, "m" for multiplet, "br" for "broad", "Hz" for Hertz, "MHz" for Megahertz, and "α", "β", "R", "S", "E", and "Z" are stereochemical designations familiar to those of skill in the art.

[0078] [Table 2]

[0079] In the illustrated examples, the following methods were used unless otherwise noted. Purification of intermediates and final products was carried out via either normal phase or reverse phase chromatography. Normal phase chromatography was carried out using pre-packed SiO2 cartridges eluting with a gradient of either hexanes and ethyl acetate or DCM and MeOH unless otherwise noted. Reverse phase preparative HPLC was performed on a C18 column with UV 220 nm or with a gradient of solvent A (90% water, 10% MeOH, 0.1% TFA) and solvent B (10% water, 90% MeOH, 0.1% TFA), or with a gradient of solvent A (95% water, 5% ACN, 0.1% TFA) and solvent B (5% water, 95% ACN, 0.1% TFA), or with a gradient of solvent A (95% water, 2% ACN, 0.1% HCOOH) and solvent B (98% ACN, 2% water, 0.1% HCOOH), or with a gradient of solvent A (95% water, 5% ACN, 10 mM NH4OAc) and solvent B (98% ACN, 2% water, 10 mM Preparative LCMS detection was performed eluting with a gradient of solvent A (98% water, 2% ACN, 0.1% NH4OH) and solvent B (98% ACN, 2% water, 0.1% NH4OH) in a gradient of 1000 mL ...

[0080] The LC / MS methods utilized for characterization of the examples are listed below. Method A: Instrumentation: Waters Acquity coupled with a Waters MICROMSS® ZQ mass spectrometer. Run a linear gradient from 2 to 98% B over 1 min, hold at 98% B for 0.5 min UV visualization at 220 nm Column: Waters BEH C18, 2.1x50mm Flow rate: 0.8mL / min (method A) Mobile phase A: 0.05% TFA, 100% water Mobile phase B: 0.05% TFA, 100% acetonitrile

[0081] Method B: Instrumentation: Shimadzu Prominence HPLC coupled with a Shimadzu LCMS-2020 mass spectrometer Run a linear gradient from 0 to 100% B over 3 min, hold at 100% B for 0.75 min UV visualization at 220 nm Column: Waters Xbridge C18, 2.1x50mm, 1.7μm particles Flow rate: 1mL / min Mobile phase A: 10 mM ammonium acetate, 95:5 water:acetonitrile Mobile phase B: 10 mM ammonium acetate, 5:95 water:acetonitrile

[0082] Method C: Instrumentation: Shimadzu Prominence HPLC coupled with a Shimadzu LCMS-2020 mass spectrometer Run a linear gradient from 0 to 100% B over 3 min, hold at 100% B for 0.75 min UV visualization at 220 nm Column: Waters Xbridge C18, 2.1x50mm, 1.7μm particles Flow rate: 1mL / min Mobile phase A: 0.1% TFA, 95:5 water:acetonitrile Mobile phase B: 0.1% TFA, 5:95 water:acetonitrile

[0083] Method D: Equipment: Waters Acquisition coupled with a Waters Micromass® ZQ mass spectrometer Run a linear gradient from 10% B to 98% B over 1 min, then hold at 98% B for 0.5 min. UV visualization at 220 nm Column: Waters Acquity GEN C18, 2.1x50mm, 1.7μm particles Flow rate: 1mL / min Mobile phase A: 0.05% TFA, 100% water Mobile phase B: 0.05% TFA, 100% acetonitrile

[0084] Method E: Instrument: Agilent 1290 Infinity II equipped with a G6135B mass spectrometer Apply a linear gradient from 0% B to 100% B over 3 min. UV visualization at 220 nm Column: Xbridge BEH XP C18 50x2.1mm, 2.5mm Flow rate: 1.1 mL / min at 50°C Mobile phase A: 10mM NH4OAc:ACN (95:05) in water Mobile phase B: 10mM NH4OAc:ACN in water (05:95)

[0085] Method F: Instrumentation: Agilent 1290 Infinity II equipped with a G6135B mass spectrometer Apply a linear gradient from 0% B to 100% B over 3 min. UV visualization at 220 nm Column: Xbridge BEH XP C18 50x2.1mm, 2.5mM Flow rate: 1.1 mL / min at 50°C Mobile phase A: 0.1% TFA in water: ACN (95:05) Mobile phase B: 0.1% TFA in water: ACN (05:95)

[0086] NMR used in the characterization of the examples 1 The H NMR spectrum shows the following frequencies: 1 H NMR: Obtained using a Bruker or JEOL® Fourier transform spectrometer operating at 400 MHz (Bruker or JEOL®) or 500 MHz (Bruker or JEOL®). Spectral data are reported in the format: chemical shift (multiplicity, coupling constant, number of hydrogens). Chemical shifts are specified in ppm downfield of the internal coordinate system of tetramethylsilane (δ units, tetramethylsilane = 0 ppm) and / or 1In the H NMR, the solvent peaks are referenced, which appear at 2.51 ppm for DMSO-d6, 3.30 ppm for CD3OD, 1.94 ppm for CD3CN, and 7.24 ppm for CDCl3.

[0087] The synthesis of the key norbornyl intermediates is outlined in Scheme IV. Norbornyl intermediates can be prepared starting from I-1 with isopropylidene bridge substitution as described in Scheme I. Diels-Alder cyclization with maleic anhydride gave compound I-2, which was reduced and deprotected to give I-3. Curtius reaction with DPPA in the free acid in the presence of trimethylsilylethanol produced I-4. The trimethylsilyl carbamate was cleaved with TFA and the amine was reprotected as trifluoroacetamide I-5. The methyl ester was converted to the amide via treatment with 4-fluoro-3-trifluoromethylaniline and trimethylaluminum to give I-6. The trifluoroacetamide was deprotected with K2CO3 and MeOH to give amine I-7.

[0088] Scheme 1 [ka]

[0089] Intermediate I-2: To a reaction vessel at 0° C. was added Et2O (100 mL), 5-(propan-2-ylidene)cyclopenta-1,3-diene (10 g, 94 mmol), and furan-2,5-dione (10 g, 100 mmol). The reaction mixture was stirred at 0° C. for 18 h, concentrated under reduced pressure, and purified via silica gel chromatography to give I-2 (3.74 g, 18.3 mmol, 19.0% yield). Intermediate I-2 is a known compound; see PCT International Application No. 2011163502, Dec. 29, 2011.

[0090] Intermediate I-3: To a reaction vessel was added I-2 (2.74 g, 13.4 mmol), EtOAc (100 mL), pyridine (0.540 mL, 6.71 mmol), and Pd / C (70 mg, 0.070 mmol). The reaction mixture was stirred at 23° C. under 1 atm H2 (H2 balloon) for 60 min, filtered through Celite, and concentrated under reduced pressure. The residue was dissolved in MeOH (50 mL) and heated at 50° C. for 12 h. The solution was concentrated under reduced pressure (azeotropic distillation with toluene 3×15 mL) to give I-3 (3.21 g, 13.5 mmol, 100% yield), which was used without further purification.

[0091] Intermediate I-4: To a reaction vessel was added I-3 (3.21 g, 13.5 mmol), Et3N (3.38 mL, 24.2 mmol), toluene (75 mL), and diphenylphosphoryl azide (4.35 mL, 20.2 mmol). The reaction mixture was stirred at 23° C. for 1 h and then heated at 85° C. for 30 min. 2-(Trimethylsilyl)ethanol (4.83 mL, 33.7 mmol) was added to the reaction mixture and after stirring at 85° C. for 66 h, the reaction mixture was cooled to 23° C. and purified via silica gel chromatography to give racemic I-4 (3.71 g, 10.5 mmol, 78% yield). LC-MS RT=1.25 min; (M+H)=354.1; Method A; Racemic I-4 was separated into individual enantiomers using chiral SFC. Preparative Chromatography Conditions: Apparatus: Thar 350 SFC; Column: Whelko-RR, 5x50cm, 10 micron; Mobile phase: 13%IPA / 87%CO2; Flow conditions: 300mL / min, 100Bar, 35°C; Detector wavelength: 220nm; Injection details: 59g of 120mg / mL in IPA / 490mL MeOH:DCM (4:1) injected 4 times at 3.5mL; Analytical Chromatography Conditions: Apparatus: Thar Analytical SFC; Column: Whelko-RR (0.46x25cm, 5 micron; Mobile phase: 5%IPA / 95%CO2; Flow conditions: 3mL / min, 140Bar, 40°C; Detector wavelength: 200-400nm UV; RT=3.50 peak #1, 4.42 peak #2; Peak #1 of the product of intermediate I-4 was collected and carried over to produce chiral I-5.

[0092] Intermediate I-5: Peak #1 of intermediate I-4 (2.87 g, 8.12 mmol) was dissolved in 10:1 DCM / TFA and stirred at room temperature for 72 h. The reaction mixture was concentrated under reduced pressure to yield (1R,2S,3R,4R)-methyl 3-amino-7-(propan-2-ylidene)bicyclo[2.2.1]heptane-2-carboxylate (1.699 g, 8.120 mmol, 100% yield), which was used without further purification. DCM (41 mL) was added to (1R,2S,3R,4R)-methyl 3-amino-7-(propan-2-ylidene)bicyclo[2.2.1]heptane-2-carboxylate (1.7 g, 8.1 mmol) and the flask was cooled to 0 °C via ice bath. TFAA (1.26 mL, 8.90 mmol) and DIEA (5.7 mL, 33 mmol) were added. The reaction mixture was allowed to warm to 23° C. and stirred for 30 min. Saturated NaHCO3 (50 mL) was added to the reaction mixture and the solution was extracted with EtOAc (3×50 mL). The organic portions were combined, dried over Na2SO4, filtered and concentrated under reduced pressure to give I-5 (2.48 g, 8.12 mmol, 100% yield), which was used without further purification. LC-MS RT=1.11 min; MS(ESI) m / z=306.1 (M+H). + ;Method A

[0093] Intermediate I-6: To a solution of intermediate I-5 (2.7 g, 8.8 mmol) in toluene (88 ml) was added trimethylaluminum (26.5 mmol) premixed with 4-fluoro-3(trifluoromethyl)aniline (29.2 mmol) as a solution in toluene (0.275 M in amine, 0.25 M in trimethylaluminum). The reaction mixture was stirred at 60° C. for 30 min. Upon cooling to room temperature, the reaction mixture was diluted with EtOAc (100 mL) and saturated Rochelle's salt (100 mL) was added. The aqueous portion was extracted with EtOAc (3×75 mL). The organic portions were combined, dried over Na2SO4, filtered, concentrated under reduced pressure, and subjected to silica gel chromatography purification, and the residue was further purified by preparative reverse-phase HPLC to give (1R,2S,3R,4R)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-7-(propan-2-ylidene)-3-(2,2,2-trifluoroacetamido)bicyclo[2.2.1]heptane-2-carboxamide I-6 (2.5 g, 5.5 mmol, 63% yield) as a yellow foam. LC-MS RT=1.20 min; MS(ESI) m / z=453.0 (M+H). + ;Method A

[0094] Intermediate I-7: Intermediate I-6 (133 mg, 0.290 mmol) was dissolved in water (2.9 mL) and MeOH (2.9 mL) and then K2CO3 (2.03 g, 1.47 mmol) was added. The reaction mixture was stirred at 40 °C for 4 h, then partitioned between water (5 mL) and extracted with EtOAc (3 x 10 mL). The organic extracts were combined, dried over Na2SO4, filtered and concentrated under reduced pressure to give I-7 (105 mg, 0.290 mmol, 100% yield), which was used without further purification. LC-MS RT = 0.82 min; MS (ESI) m / z = 357.1 (M + H). + ;Method A

[0095] Scheme Ia Norbornyl intermediate IIa-8 can also be prepared from furan-2,5-dione and ferrocenium hexafluorophosphate by the general route shown in Scheme Ia. Diels-Alder condensation followed by hydrolysis to IIa-2 and Curtius rearrangement to the intermediate amine, which is reduced under hydrogenation conditions and subsequently protected to generate intermediate IIa-3. Cleavage of the benzyl ester affords NHR. 1 R 2 This was cross-coupled to produce the intermediate with the general structure IIa-5. The C7 hydroxy group was converted to a ketone, followed by Wittig olefination to produce the major isomer intermediate IIa-8. The major isomer was separated from the minor isomer by chromatography, and the racemate was separated into enantiopure IIa-8(-).

[0096] [ka]

[0097] Scheme II shows how intermediate I-6 is converted to an olefin bromide intermediate that is amenable to cross-coupling at the C-7 methylidene. Scheme II [ka]

[0098] Intermediate II-1 To a reaction vessel was added intermediate I-6 (110 mg, 0.243 mmol) and EtOAc (2 mL). The reaction mixture was cooled to -78°C and O3 was bubbled through the solution until the solution turned light purple / blue. N2 was then bubbled through the solution at -78°C to remove excess O3 (the solution became colorless). Dimethylsulfide (0.43 mL, 4.8 mmol) was then added at -78°C and the reaction mixture was allowed to warm to room temperature and stirred at room temperature for 12 hours. After concentration under reduced pressure, the residue was dissolved in EtOAc and filtered through silica gel to afford (1R,2S,3R,4S)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-7-oxo-3-(2,2,2-trifluoroacetamido)bicyclo[2.2.1]heptane-2-carboxamide (II-1, 101 mg, 0.237 mmol, 97.0% yield) after removal of the solvent under reduced pressure. 1 H NMR (500MHz, CDCl3) δ 9.61(brd,J=6.3Hz,1H), 7.76(dd,J=5.9, 2.6Hz,1H), 7.71(dt,J=8.9, 3.4Hz,1H), 7.66(s,1H), 7.23(t,J=9.4Hz,1H), 4.70(dt,J=10.3, 5.3 Hz,1H), 3.33(dd,J=10.5, 4.4Hz,1H), 2.54(t,J=4.3Hz,1H), 2.42(t,J=4.1Hz,1H), 2.20-2.10(m,1H), 2.06-1.99(m,1H), 1.96-1.81(m,2H)

[0099] Intermediate II-2: To the reaction vessel, bromo(methyl)triphenylphosphorane (419 mg, 1.17 mmol) (fine powder obtained by grinding commercial product) and THF (7 mL) were added. The reaction mixture was cooled to -78°C and KHMDS (1.2 mL, 1.2 mmol) was added. The reaction mixture was allowed to stir vigorously at -78°C for 30 min and II-1 (100 mg, 0.24 mmol) was added at -78°C. After stirring at -78°C for an additional 10 min, the reaction mixture was allowed to warm to 23°C and stirred for an additional 1.5 h. The reaction mixture was cooled to -40°C and quenched by the addition of saturated NaHCO3. The resulting solution was extracted with EtOAc. The organic portions were combined, dried over Na2SO4, filtered, concentrated under reduced pressure, and purified via silica gel chromatography to give II-2 (71 mg, 0.17 mmol, 71% yield). LCMS RT=1.16 min;(M+H)=425.0;Method A

[0100] Intermediates II-3 and II-4: To the reaction vessel was added II-2 (71 mg, 0.17 mmol), DCM (3 mL), and Br2 (0.03 mL, 0.6 mmol). The reaction mixture was stirred at 23° C. for 20 min, concentrated under reduced pressure, and excess Br2 was quenched using a trap with saturated Na2S2O3. The resulting dibromide was dissolved in THF (3 mL). After cooling to −78° C., KHMDS (1.0 mL, 1.0 mmol) was added. The reaction mixture was kept at −78° C. for 12 h and −40° C. for 2 h, quenched by the addition of saturated NaHCO3 at −40° C., and the resulting solution was extracted with EtOAc. The organic phase was collected, dried over Na2SO4, filtered, concentrated under reduced pressure, and purified via silica gel chromatography to give II-4 (27 mg, 0.050 mmol, 32% yield) (peak 2); LCMS RT = 1.19 min; (M+H) = 504.9; Method A: and the corresponding E-isomer II-3 (28 mg, 0.06 mmol, 33% yield) (peak 1).

[0101] Racemic II-4 (4 grams) was produced as above and separated into its individual enantiomers using chiral SFC. Preparative chromatographic conditions: Apparatus: Thar 350 SFC; Column: Chiralcel OD-H, 5x50cm, 5 microns; Mobile phase: 20% MeOH / 80% CO2; Flow conditions: 340mL / min, 100Bar, 35°C; Detector wavelength: 220nm; Injection details: 3.75mL of 30mg / mL in MeOH injected: Peak #1 RT=7.81min, Peak #2 RT=10.97min: Peak #1 of II-4 (1.9 grams) was collected and carried forward to produce chiral II-5.

[0102] Intermediate II-5: To the reaction vessel was added MeOH (3 mL) and AcCl (0.3 mL, 4.2 mmol). After stirring for 5 min, chiral peak #1 II-4 (75 mg, 0.15 mmol) was added and the reaction mixture was stirred at 40° C. for 48 h. The reaction mixture was concentrated under reduced pressure to yield II-5 (67 mg, 0.16 mmol, 100%), which was used without further purification. LC-MS RT=0.78 min; (M+H)=408.9; Method A

[0103] Scheme III [ka]

[0104] Intermediate III-1: To the reaction vessel was added diethyl benzylphosphonate (375 mg, 1.64 mmol) and THF (10 mL). The reaction mixture was cooled to -78°C and KHMDS (1.6 mL, 1.6 mmol) was added. The reaction mixture was stirred at -78°C for 10 min and intermediate II-1 (140 mg, 0.328 mmol) was added. After 20 min, the reaction mixture was allowed to warm to room temperature and stirred at room temperature for 2 h. The reaction mixture was quenched by the addition of saturated NaHCO3 and the solution was extracted with EtOAc. The organic portions were combined, dried over Na2SO4, filtered, concentrated, and subjected to silica gel chromatography purification to give the E-isomer by-product (111 mg, 0.222 mmol, 67.5% yield) and (1R,2S,3R,4R,Z)-7-benzylidine-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2,2,2-trifluoroacetamido)bicyclo[2.2.1]heptane-2-carboxamide (III-1, 49 mg, 0.098 mmol, 30% yield). RT=1.23 min; MS(ESI) m / z=501.1 (M+H). + ;Method A

[0105] Intermediate III-2: Acetyl chloride (0.3 mL, 4 mmol) was added dropwise to a vial containing MeOH (3 mL) cooled to 0° C. (ice / water bath). The resulting solution was stirred at room temperature for 10 min and then added to III-1 (94 mg, 0.19 mmol). The reaction mixture was stirred at 40° C. for 48 h and concentrated under reduced pressure to give (1R,2S,3R,4R)-3-amino-7-((Z)-benzylidene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)bicyclo[2.2.1]heptane-2-carboxamide (III-2, 73 mg, 0.18 mmol, 96% yield). RT=0.87 min; MS(ESI) m / z=405.1 (M+H). + Method A: It was used without further purification.

[0106] Scheme IV shows a general route to introduce functional groups on the C7 bridge, such as, but not limited to, cyclopropyl, cyclobutyl, and nBu, in a manner similar to Scheme II.

[0107] Scheme IV [ka]

[0108] Intermediate IV-1a: A solution of II-4 (1.00 g, 1.98 mmol) in THF (9.9 mL) was treated with PdCl2(dppf) (0.073 g, 0.099 mmol) under N2, then cyclopropylzinc(II) bromide (15.9 mL, 7.95 mmol) was added and the reaction mixture was heated at 60 °C for 2 h. The cooled reaction mixture was extracted from brine with EtOAc, and the organic portions were combined and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give (1R,2S,3R,4R,Z)-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2,2,2-trifluoroacetamido)bicyclo[2.2.1]heptane-2-carboxamide (IV-1a, 646 mg, 1.39 mmol, 70.0% yield). LC-MS RT=1.07min;MS(ESI) m / z=492.1(M+H) + ;Method A

[0109] Intermediate IV-2: A solution of IV-1a (646 mg, 1.39 mmol) in MeOH (9.3 mL) was treated with K2CO3 (961 mg, 6.96 mmol) in water (4.6 mL) and the reaction mixture was stirred for 18 h. The reaction mixture was extracted with EtOAc from the phosphate buffer. The organic layer was concentrated to give (1R,2S,3R,4R,Z)-3-amino-7-(cyclopropylmethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)bicyclo[2.2.1]heptane-2-carboxamide, which was used without further purification (IV-2a, 512 mg, 1.39 mmol, 100% yield). RT=0.84 min; MS(ESI) m / z=369.1 (M+H). + ;Method A

[0110] Intermediates IV-1b,c and IV-2b,c were prepared similarly from commercially available organozinc reagents.

[0111] Scheme V [ka]

[0112] Intermediate V-1: Intermediate V-1 was prepared from II-4. To a 250 mL round-bottom flask charged with methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (2.5 mL, 20 mmol) in anhydrous DMF (50 mL), a suspension of II-4 and CuI (2.3 g, 12 mmol) in anhydrous DMF (100 mL) and HMPA (8.0 mL, 19 mmol) were added dropwise via a dropping funnel, and the reaction mixture was heated at 75° C. under an inert nitrogen atmosphere for 16 h. The reaction mixture was cooled, filtered and purified by silica gel chromatography to give V-1 (3.0 g, 6.1 mmol, 77% yield). 1H NMR (500MHz, CDCl3) δ 9.38(brd,J=6.1Hz,1H), 7.77-7.69(m,2H), 7.46(s,1H), 7.24(t,J=9.1Hz,1H), 5.62(q,J=7.2Hz,1H), 4.50(dt,J= 10.5, 5.3Hz,1H), 3.50-3.42(m,1H), 3.13-3.04(m,1H), 2.89(t,J=4.0Hz,1H), 2.02-1.90(m,2H), 1.76-1.60(m,2H)

[0113] Intermediate V-2: Intermediate V-2 was prepared from V-1. MeOH (1.5 mL) and acetyl chloride (2.1 mmol) were charged to a 2-dram vial and stirred at 23° C. for 5 min. V-1 was added to the reaction vial and the contents were heated at 40° C. for 24 h. Concentration with a stream of nitrogen afforded V-2 as the HCl salt, which was used without further purification. LC-MS RT=0.75 min; MS(ESI) m / z=397.1 (M+H). + ;Method A

[0114] Example 2 [ka]

[0115] Intermediate VI-1 [ka]

[0116] A slurry of 4-methoxybenzenesulfonohydrazide (595 mg, 2.94 mmol), ethyl 3-oxocyclohexane-1-carboxylate (500 mg, 2.94 mmol) in dioxane (14.7 mL) was heated at 80° C. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography to give ethyl (Z)-3-(2-((4-methoxyphenyl)sulfonyl)hydrazinylidene)cyclohexane-1-carboxylate (VI-1, 904 mg, 2.55 mmol, 87% yield), which was used without further purification.

[0117] Intermediate VI-2 [ka]

[0118] A slurry of (3-(tert-butoxycarbonyl)phenyl)boronic acid (0.329 g, 1.48 mmol), intermediate VI-1 (0.350 g, 0.988 mmol), and Cs2CO3 (0.804 g, 2.47 mmol) in dioxane (4.9 mL) was heated at 110 °C for 18 h. The reaction mixture was partitioned between water and EtOAc. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography to give tert-butyl 3-(3-(ethoxycarbonyl)cyclohexyl)benzoate (VI-2, 192 mg, 0.578 mmol, 58.5% yield). MS (ESI) m / z = 277 (M + H-tBu). +

[0119] Intermediate VI-3 [ka]

[0120] A solution of intermediate VI-2 (140 mg, 0.421 mmol) in THF (3.5 mL) was treated with LiOH (20 mg, 0.84 mmol) in water (0.7 mL). The reaction mixture was adjusted to pH 3 by adding dilute HCl (1N), filtered through Celite, and concentrated under reduced pressure to give 3-(3-(tert-butoxycarbonyl)phenyl)cyclohexane-1-carboxylic acid (VI-3, 128 mg, 0.421 mmol, 100% yield), which was used without further purification. MS (ESI) m / z=249 (M+H-tBu). +

[0121] Intermediate 1-1 [ka]

[0122] To intermediate VI-3 (121 mg, 0.280 mmol) dissolved in MeCN (2.8 mL) was added Hunig's base (0.25 mL, 1.4 mmol), intermediate V-2 (128 mg, 0.421 mmol), and HATU (128 mg, 0.336 mmol), and the mixture was stirred for 18 h. The reaction mixture was extracted with EtOAc from water. The organic layer was concentrated under reduced pressure, and the residue was purified by silica gel chromatography to give tert-butyl 3-(3-(((1R,2R,3S,4R,Z)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)-7-(2,2,2-trifluoroethylidene)bicyclo[2.2.1]heptan-2-yl)carbamoyl)cyclohexyl)benzoate (2-1, 130 mg, 0.190 mmol, 67.9% yield). MS(ESI) m / z=627(M+H-tBu) +

[0123] Example 1 A solution of 1-1 (130 mg, 0.190 mmol) in DCM (0.7 mL) was treated with TFA (0.3 mL). After 2 h, the reaction mixture was concentrated under reduced pressure and the residue was purified by reverse phase HPLC to give 3-(3-(((1R,2R,3S,4R,Z)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)-7-(2,2,2-trifluoroethylidene)bicyclo[2.2.1]heptan-2-yl)carbamoyl)cyclohexyl)benzoic acid as a mixture of four stereoisomers. The diastereomers were partially resolved by SFC (Chiral AS, 30x250 mm, 5 micron, 100 mL / min, 40°C, 120 Bar, 85% CO2 / 15% MeOH w / 0.1% DEA (isocratic)).

[0124] Example 1: Peak 1 (single isomer, RT=4.49 min): 3-(3-(((1R,2R,3S,4R,Z)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)-7-(2,2,2-trifluoroethylidene)bicyclo[2.2.1]heptan-2-yl)carbamoyl)cyclohexyl)benzoic acid (1.1 mg, 1.6 μmol, 0.87% yield); 1 H NMR (500MHz, DMSO-d6) δ 10.56(s,1H), 8.38(brd,J=7.2Hz,1H), 8.16-8.05(m,1H), 7.82-7.71(m,3H), 7 .56-7.37(m,3H), 5.90(brd,J=8.1Hz,1H), 4.42-4.35(m,1H), 3.17(brdd,J=10 .4, 4.3Hz,1H), 3.09(brd,J=4.6Hz,1H), 2.99-2.87(m,2H), 2.69(brs,1H), 2.1 5-1.93(m,4H), 1.89-1.80(m,1H), 1.74-1.60(m,2H), 1.55-1.40(m,6H);LC-MS RT2.02min;MS(ESI) m / z=627.14(M+H) + ;Method C

[0125] Example 2: Peak 2 (single isomer, RT=6.33 min): 3-(3-(((1R,2R,3S,4R,Z)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)-7-(2,2,2-trifluoroethylidene)bicyclo[2.2.1]heptan-2-yl)carbamoyl)cyclohexyl)benzoic acid (7.7 mg, 0.012 mmol, 6.2% yield); 1H NMR (500MHz, DMSO-d6) δ 10.47(s,1H), 8.19(brd,J=8.0Hz,1H), 8.15-8.08(m,1H), 7.81-7.67(m,3H), 7.53-7.35(m,3H), 5.85(q,J=7.6Hz,1H), 4.36(brs,1H), LC-MS RT2.40min;MS(ESI) m / z=627.17(M+H) + ;Method C

[0126] Example 3 Peak 3 (mixture of two diastereomers, RT = 17.34 min): 3-(3-(((1R,2R,3S,4R,Z)-3-((4-fluoro-3-(trifluoromethyl)phenyl)carbamoyl)-7-(2,2,2-trifluoroethylidene)bicyclo[2.2.1]heptan-2-yl)carbamoyl)cyclohexyl)benzoic acid (13.6 mg, 0.021 mmol, 11.2% yield); 1 H NMR (500MHz, DMSO-d6) δ 10.34(brs,1H), 8.15(brs,1H), 7.99(brd,J=2.1Hz,1H), 7.79-7.57(m,3H), 7.37-7.18(m,3H), 5.88-5.79(m,1H), 4.46-4.35(m,1H), 3.08 (brd,J=10.4Hz,1H), 3.01-2.93(m,1H), 2.89(brs,1H), 2.49-2.38(m,2H), 2.26-1.99(m,2H), 1.87-1.57(m,4H), 1.53-1.18(m,7H);LC-MS RT2.42min;MS(ESI) m / z=627.17(M+H) + ;Method C

[0127] Example 4 [ka]

[0128] A solution of intermediate V-2 (10 mg, 0.025 mmol) in MeCN (1 mL) was treated with Hunig's base (5 μL, 0.03 mmol) and 4-chloro-2-isocyanato-1-methoxybenzene (6.0 mg, 0.033 mmol) and BOP reagent, and the reaction mixture was allowed to stir at room temperature for 18 h. The reaction mixture was concentrated under reduced pressure, and the residue was purified by reverse phase HPLC to give (1R,2S,3R,4R,Z)-3-(3-(5-chloro-2-methoxyphenyl)ureido)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-7-(2,2,2-trifluoroethylidene)bicyclo[2.2.1]heptane-2-carboxamide (5, 5.6 mg, 8.7 μmol, 34% yield). 1 H NMR (500MHz, DMSO-d6) δ 10.32(s,1H), 8.60(s,1H), 8.12(brd,J=4.6Hz,1H), 8.05(d,J=1.8Hz,1H), 7.70-7.61(m,1H), 7.52-7.35(m,2H), 6.95-6.80(m,2H), 5.87(brd,J=7.9H z,1H), 4.52-4.39(m,1H), 3.80(s,3H), 3.21-3.10(m,1H), 3.01-2.84(m,2H ), 2.37(brs,1H), 2.05(brd,J=16.8Hz,1H), 1.50(brt,J=11.9Hz,2H);LC-MS RT2.52min;MS(ESI) m / z=580.11(M+H) + ;Method C

[0129] Example 12 [ka]

[0130] Intermediate 12-1 [ka]

[0131] A solution of (1S,3R)-3-(methoxycarbonyl)cyclohexane-1-carboxylic acid (0.200 g, 1.07 mmol) in THF (3.6 mL) was treated with borane-tetrahydrofuran complex (1.6 mL, 1.6 mmol) at 0 °C. The reaction mixture was quenched with NH4Cl solution and extracted with EtOAc. The organic portion was concentrated under reduced pressure and the residue was used without further manipulation as methyl (1R,3S)-3-(hydroxymethyl)cyclohexane-1-carboxylate (0.185 g, 1.07 mmol, 100% yield). LC-MS (M+H) = 173.1; HPLC RT = 0.91 min; Method A

[0132] Intermediate 12-2 [ka]

[0133] A solution of oxalyl chloride (0.45 mL, 5.1 mmol) in 1 mL of DCM was treated with DMSO (0.72 mL, 10. mmol) in DCM (1 mL) at -78 °C. After 15 min, the reaction mixture was treated with 12-1 (175 mg, 1.02 mmol) in 3 mL of DCM. After 30 min, the resulting solution was treated with TEA (2.1 mL, 15 mmol) and allowed to warm slowly to room temperature. 1N HCl was added to the reaction mixture and the solution was extracted with DCM. The organic portion was concentrated under reduced pressure and the residue was used without further manipulation as methyl (1R,3S)-3-formylcyclohexane-1-carboxylate (173 mg, 1.02 mmol, 100% yield). 1 H NMR (500MHz, CDCl3) δ 9.64(d,J=1.2Hz,1H), 3.71(s,3H), 2.62-2.55(m,4H), 2.06-1.94(m,4H), 1.41-1.36(m,2H)

[0134] Intermediate 12-3 [ka]

[0135] A solution of 12-2 (170 mg, 0.999 mmol) in DCM (1.0 mL) was treated with hydroxylamine hydrochloride (69.4 mg, 0.999 mmol) followed by TEA (0.25 mL, 1.8 mmol) and stirred for 14 h. The reaction mixture was then partitioned between water and EtOAc. The organic portion was concentrated under reduced pressure and the residue was used without further manipulation as methyl (1R,3S)-3-((E)-(hydroxyimino)methyl)cyclohexane-1-carboxylate (185 mg, 0.999 mmol, 100% yield). LC-MS (M+H)=186.1; HPLC RT=0.96 min; Method A

[0136] Intermediate 12-4 [ka] A solution of 12-3 (0.19 g, 1.0 mmol) in DMF (5 mL) was treated with NCS (0.133 g, 0.999 mmol). After 3 h, the reaction mixture was partitioned between water and EtOAc. The organic portion was concentrated under reduced pressure, then the residual methyl (1R,3S)-3-((Z)-chloro(hydroxyimino)methyl)cyclohexane-1-carboxylate was dissolved in DCM (10 mL) and treated with 2,5-dihydrofuran (84 mg, 1.2 mmol) followed by TEA (2.0 mL, 14 mmol) and stirred for 14 h. The reaction mixture was concentrated under reduced pressure and the residue was then purified by silica gel chromatography (in-line light scattering detection) to give methyl (1R,3S)-3-(3a,4,6,6a-tetrahydrofuro[3,4-d]isoxazol-3-yl)cyclohexane-1-carboxylate (53 mg, 0.21 mmol, 21% yield). LC-MS (M+H)=254.2; HPLC RT=0.96 min; Method A

[0137] Intermediate 12-5 [ka]

[0138] 12-4 (52 mg, 0.21 mmol) in THF (3.4 mL) containing a few drops of MeOH was treated with LiOH (26 mg, 0.62 mmol) in water (0.7 mL) and the reaction mixture was stirred for 14 h. 1N HCl was added to the reaction mixture and the resulting solution was extracted with EtOAc. The organic portion was concentrated to give (1R,3S)-3-(3a,4,6,6a-tetrahydrofuro[3,4-d]isoxazol-3-yl)cyclohexane-1-carboxylic acid (49 mg, 0.21 mmol, 100% yield). LC-MS (M+H)=240.2; HPLC RT=0.83 min; Method A

[0139] Example 12: Prepared from intermediate 12-5 and IV-2a following the general procedure detailed for intermediate 1-1 to give four isomeric products which were resolved by SFC separation: Preparative chromatographic conditions: Column: Chiral IC, 21x250mm 5 micron, Mobile phase: 65%CO2 / 35%IPA w / 0.1%DEA, Flow conditions: 60mL / min; Analytical chromatographic conditions (pre-preparative): Column: Chiral IC, 4.6x150mm, 5 micron, Mobile phase: 65%CO2 / 35%IPA w / 0.1%DEA RT (peak 1): 3.2 min, Peak 1 (Example 12, 1.7 mg, 2.8 μmol, 1.5% yield): LC-MS (M+H)=590.4, HPLC RT=2.53 min; Method C; 1H NMR (500MHz, DMSO-d6) δ 10.12(s,1H), 7.92(brd,J=7.6Hz,1H), 7.83(brd,J=4.3Hz,1H), 7.54(brdd,J=5.0, 3.2Hz,1H), 7.23(brd,J=9.8Hz,1H), 4.77(dd,J=9.2, 3.4Hz,1H), 4.39(d,J=9.5Hz,1H), 4.07-3.94(m,1H), 3.72(brd,J=10.7Hz,2H), 3.50(brt,J=7.6Hz,1H) , 3.30-3.20 (m, 1H), 2.79 (brdd, J = 10.7, 4.0 Hz, 1H), 2.67 (brs, 1H), 2.42 (brs, 1H), 2.31 (s, 1H), 2.19-1.99 (m, 2H), 1.73-1.59 (m, 3H), 1.57-1.47 (m, 3H), 1.31-0.97 (m, 6H), 0.85 (q, J = 12.2 Hz, 1H), 0.53-0.41 (m, 2H). Some protons were obscured by solvent suppression.

[0140] RT (peak 2): 4.1 min, Example 13 (2.6 mg, 4.4 μmol, 2.4% yield), see Table for characterization information. RT (peak 3): 5.0 min, Example 14 (2.2 mg, 3.7 μmol, 2.0% yield), see Table for characterization information. RT (peak 4): 8.1 min, Example 15 (2.5 mg, 4.2 μmol, 2.3% yield), see Table for characterization information.

[0141] Further compounds of the present invention are listed in Tables 2 and 3. Table 2 [Table 3] [Table 4] [Table 5]

[0142] Table 3 [Table 6] [Table 7] [Table 8] [Table 9] [Table 10] [Table 11] [Table 12] [Table 13] [Table 14]

[0143] It will be apparent to those skilled in the art that the present disclosure is not limited to the illustrative embodiments described above, but may be embodied in other specific forms without departing from its essential attributes. The embodiments are therefore to be considered in all respects as illustrative and not restrictive, and reference should be made to the appended claims rather than to the embodiments described above, and thus all changes that come within the meaning and range of equivalence of the claims are intended to be embraced by the present invention.

Claims

1. Formula (I): 【Chemistry 1】 [In the formula: R １ Halo, CN, C １－７ Alkyl (0 to 3 R ６ substituted with), C ２－７ Alkenyl (0 to 3 R ６ substituted with), C ２－７ Alkynyl (0 to 3 R ６ substituted with), C ３－６ Cycloalkyl (0 to 3 R １４ substituted with), C ３－６ Cycloalkenyl (0 to 3 R １４ aryl (substituted with 0 to 3 R １４ substituted with), or 4- to 6-membered heterocyclyl (O, S(=O) ｐ , N, and NR １４ａ and 0 to 3 R １４ substituted with R ２ is H or C １－３ is alkyl; R ３ is -NR ａ C(=O)R ５ , -NR ａ C(=O)(CR ｄ R ｄ ) １－２ R ７ , or -NR ａ C(=O)NR ａ R ７ and R ４ Halo, CN, C １－４ Alkyl (substituted with 0 to 5 halo substituents), —OH, —OC １－４ alkyl (substituted with 0-5 halo substituents), —S(═O) ｐ R ｃ or aryl; R ５ is C １－８ Alkyl (0 to 4 R １１ substituted with) or C ３－６ Cycloalkyl (0 to 4 R ８ and 0 to 2 R ９ substituted with R ６ Ha, halo, OH, C ３－６ cycloalkyl, or aryl; R ７ is an aryl (0 to 4 R ８ and 0 to 2 R ９ substituted with R ８ Ha-OR ｂ and R ９ is halo, CN, phenyl (0-3 R １０ and 0 to 2 R １１ substituted with), or 3- to 12-membered heterocyclyl (O, S(═O) ｐ , N, and NR １１ａ and 0 to 3 R １０ and 0 to 2 R １１ substituted with R １０ is halo, CN, or C １－４ is alkyl; R １１ is C １－３ alkyl (0 to 1 R １２ and 0 to 1 R １３ substituted with), -OR ｂ , -NR ａ R ａ , -NR ａ C(=O)R ｂ , -NR ａ C(=O)OR ｂ , -NR ａ C(=O)NR ａ R ａ , -NR ａ S (= O) ｐ R ｃ , -C(=O)R ｂ , -C(=O)OR ｂ , —C(═O)NR ａ R ａ , —C(═O)NR ａ S (= O) ｐ R ｃ , -OC(=O)R ｂ , -S(=O) ｐ R ｃ , -S(=O) ｐ NR ａ R ａ , C ３－１０ Carbocyclyl (0 to 5 R ｅ substituted with), 4- to 6-membered heterocyclyl (O, S(=O) ｐ , N and NR １５ and 0 to 5 R ｅ substituted with R １１ａ is H or C １－４ Alkyl (0 to 2 R ｅ substituted with R １２ is halo, -C(=O)OR ｂ , -C(=O)NHR ａ , -C(=O)NHOR ｂ , or C １－４ alkyl (substituted with 0-3 halo or OH substituents); R １３ is -OR ｂ , -NR ａ R ａ , -NR ａ C(=O)R ｂ , -NR ａ C(=O)OR ｂ , -NR ａ S (= O) ｐ R ｃ , -NR ａ S (O) ｐ NR ａ R ａ , -OC(=O)NR ａ R ａ , -OC(=O)NR ａ OR ｂ , -S(=O) ｐ NR ａ R ａ , or -S(O) ｐ R ｃ and R １４ Halo, CN, C １－４ alkyl (substituted with 0 to 3 halo substituents), —OC １－４ alkyl (substituted with 0 to 3 halo substituents), —(CH ２ ) ０－３ -NR ａ R ａ , -(CH ２ ) ０－３ -aryl (0 to 3 R ｅ substituted with), —O-aryl (substituted with 0 to 3 R ｅ substituted with), or -(CH ２ ) ０－３ -3 to 12-membered heterocyclyl (O, S(=O) ｐ and N, and 0 to 3 R ｅ substituted with R １４ａ is H, C(=O)C １－４ Alkyl, or C １－３ alkyl (substituted with 0-3 aryl substituents substituted with 0-2 halo substituents); R １５ is H, C １－３ alkyl, or aryl; R １６ is C １－３ alkyl (0 to 1 R ｅ substituted with), —C(═O)R ｂ , -C(=O)OR ｂ , —C(═O)NR ａ R ａ , —C(═O)NR ａ S (= O) ｐ R ｃ , -OC(=O)R ｂ , -S(=O) ｐ R ｃ , or -S(=O) ｐ NR ａ R ａ and R ａ is H, C １－５ Alkyl (0 to 5 R ｅ substituted with), C ２－５ alkenyl (0 to 5 R ｅ substituted with), C ２－５ Alkynyl (0 to 5 R ｅ substituted with), -(CH ２ ) ｎ -C ３－１０ Carbocyclyl (0 to 5 R ｅ substituted with), or -(CH ２ ) ｎ -3 to 12-membered heterocyclyl (O, S(=O) ｐ and N, and 0 to 5 R ｅ or R ａ and R ａ and together with the nitrogen atom to which they are attached form a 3- to 12-membered heterocyclyl (O, S(=O) ｐ and N, and 0 to 5 R ｅ substituted with; R ｂ is H, C １－５ Alkyl (0 to 5 R ｅ substituted with), C ２－５ alkenyl (0 to 5 R ｅ substituted with), C ２－５ Alkynyl (0 to 5 R ｅ substituted with), -(CH ２ ) ｎ -C ３－１０ Carbocyclyl (0 to 5 R ｅ substituted with), or -(CH ２ ) ｎ -3 to 12-membered heterocyclyl (O, S(=O) ｐ and N, and 0 to 5 R ｅ substituted with R ｃ is C １－５ Alkyl (0 to 5 R ｅ substituted with), C ２－５ alkenyl (0 to 5 R ｅ substituted with), C ２－５ Alkynyl (0 to 5 R ｅ substituted with), C ３－６ Carbocyclyl, or 3- to 12-membered heterocyclyl (O, S(=O) ｐ and N; R ｄ is H, -OR ｂ , or C １－５ Alkyl (0 to 5 R ｅ substituted with R ｅ Halo, CN, =O, C １－６ Alkyl (0 to 5 R ｇ substituted with), C ２－６ alkenyl (0 to 5 R ｇ substituted with), C ２－６ Alkynyl (0 to 5 R ｇ substituted with), -(CH ２ ) ｎ -C ３－１０ Carbocyclyl (0 to 5 R ｇ substituted with), -(CH ２ ) ｎ -3 to 12-membered heterocyclyl (O, S(=O) ｐ and N, and 0 to 5 R ｇ substituted with), -(CH ２ ) ｎ OR ｆ , -C(=O)OR ｆ , —C(═O)NR ｆ R ｆ , -NR ｆ C(=O)R ｆ , -S(=O) ｐ R ｆ , -NR ｆ C(=O)OR ｆ , -OC(=O)NR ｆ R ｆ , or -(CH ２ ) ｎ NR ｆ R ｆ and R ｆ is H, C １－５ Alkyl, C ３－６ cycloalkyl, or aryl; or R ｆ and R ｆ and together with the nitrogen atom to which they are attached form a 3- to 12-membered heterocyclyl (O, S(=O) ｐ and N; R ｇ Halo, CN, OH, C １－６ Alkyl, C ３－６ cycloalkyl, or aryl; n is 0, 1, 2, or 3; p is 0, 1, or 2. or a pharmaceutically acceptable salt thereof.

2. Formula (II): 【Chemistry 2】 [In the formula: R １ Ha, Halo, C １－４ alkyl (substituted with 0-4 halo), C ３－６ cycloalkyl, or phenyl; R ２ is H; R ４ is halo or C １－４ alkyl (substituted with 0-4 halo substituents); R ５ is C ３－６ Cycloalkyl (0 to 1 R ９ substituted with R ９ is halo, CN, or phenyl (0-1 R １０ and 0 to 1 R １１ (replaced by 【Transformation 3】 and R １０ is halo, CN, or C １－４ is alkyl; R １１ is -OH, -OC １－４ Alkyl, or —C(═O)OR ｂ and R １１ａ is H or C １－３ is alkyl; R ａ is H or C １－４ alkyl; R ｂ is H or C １－４ alkyl] 2. The compound of claim 1, wherein: or a pharmaceutically acceptable salt thereof.

3. Formula (II): 【Chemistry 4】 [In the formula: R １ Ha, Halo, C １－４ alkyl (substituted with 0 to 4 halo substituents), C ３－６ cycloalkyl, or phenyl; R ２ is H; R ４ is halo or C １－４ alkyl (substituted with 0-4 halo substituents); R ５ is C １－７ alkyl (0 to 1 R １１ substituted with R １１ is -OR ｂ , -C(=O)R ｂ , -C(=O)OR ｂ or —C(═O)NR ａ R ａ and R ａ is H or C １－４ alkyl; R ｂ is H or C １－４ alkyl] 2. The compound of claim 1, wherein: or a pharmaceutically acceptable salt thereof.

4. Formula (III): 【Transformation 5】 [In the formula: R １ Ha, Halo, C １－４ alkyl (substituted with 0 to 4 halo substituents), C ３－６ cycloalkyl, or phenyl; R ２ is H; R ４ is halo or C １－４ alkyl (substituted with 0-4 halo substituents); R ７ is aryl (0 to 1 R ８ and 0 to 1 R ９ substituted with R ８ Ha-OR ｂ and R ９ is halo, CN, or phenyl (0-3 R １０ and 0 to 2 R １１ substituted with R １０ Halo, CN, C １－４ Alkyl, —OH, or —OC １－４ is alkyl; R １１ is -OR ｂ or -C(=O)OR ｂ and R ａ is H or C １－４ is alkyl; R ｂ is H, C １－４ alkyl, or phenyl; R ｄ is —OH or —OC １－４ alkyl] 2. The compound of claim 1, wherein: or a pharmaceutically acceptable salt thereof.

5. Formula (IV): 【Transformation 6】 [In the formula: R １ Ha, Halo, C １－４ alkyl (substituted with 0 to 4 halo substituents), C ３－６ cycloalkyl, or phenyl; R ２ is H; R ４ is halo or C １－４ alkyl (substituted with 0-4 halo substituents); R ７ is aryl (0 to 1 R ８ and 0 to 1 R ９ substituted with R ８ Ha-OC １－４ alkyl (substituted with 0-5 halo or OH substituents); R ９ is halo, CN, or phenyl (0-3 R １０ and 0 to 2 R １１ substituted with R １０ Halo, CN, C １－４ Alkyl, —OH, or —OC １－４ is alkyl; R １１ is -OR ｂ or -C(=O)OR ｂ and R ａ is H or C １－４ alkyl; R ｂ is H, C １－４ alkyl, or phenyl] 3. The compound of claim 2, wherein: or a pharmaceutically acceptable salt thereof.

6. 10. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

7. The pharmaceutical composition of claim 6 for treating a relaxin-related disease.

8. 8. The pharmaceutical composition of claim 7, wherein the disease is selected from the group consisting of angina, unstable angina, myocardial infarction, heart failure, acute coronary artery disease, acute heart failure, chronic heart failure, and cardiac ectopic damage.

9. The pharmaceutical composition according to claim 8, wherein the disease is heart failure.

10. The pharmaceutical composition of claim 7, wherein the disease is fibrosis.

Images